$13.68
-0.02 (-0.15%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where OGN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
Of the 500 shown: 449 interventional · 51 observational · 260 with posted results
Held by 14 tracked-famous managers (Man Group plc, MILLENNIUM MANAGEMENT LLC, Balyasny Asset Management L.P., AQR CAPITAL MANAGEMENT LLC, GABELLI FUNDS LLC, +9 more) · FINRA short interest 6.2 days to cover (settled 2026-07-31) · government filings 180d: 2 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisNCT07265479Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Tapinarof cream, 1%, Vehicle Cream | Atopic Dermatitis | 187 | Aug 2027 | ≤ 377 d | 2026-08-12 |
| Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsNCT05172726Adverse Events (AEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: tapinarof cream, 1% | Plaque Psoriasis | 58 | Oct 2026 | ≤ 73 d | 2026-04-17 |
| A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related PainNCT05560646results2026-05-08Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: OG-6219, Placebo | Endometriosis | 354 | 2025-05-28actual | — | 2026-05-08 |
| A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)NCT04626596Pregnancy Rate (Pearl Index) for At Risk Cycles During Extended-Duration UseOpen-label · Prevention | Phase 3 | Completed | Combination product: Radiopaque Etonogestrel (ENG) Implant | Contraception | 498 | 2024-12-30actual | — | 2026-02-18 |
| Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk PatientsNCT05761444results2025-09-09Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 6Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Atozet 10/40 mg or 10/80 mg, Lipitor 40 mg or 80 mg | Atherosclerotic Cardiovascular Disease | 137 | 2024-09-04actual | — | 2025-09-09 |
| Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic DermatitisNCT05142774results2025-08-13Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tapinarof cream, 1% | Atopic Dermatitis | 728 | 2024-02-29actual | — | 2025-08-13 |
| Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral ContraceptiveNCT05264506results2025-11-21Number of Participants With On-treatment PregnanciesOpen-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision to stop the study early and complete all required study close-out activities. This decision was made for business reasons unrelated to safety. None of the pre-specified efficacy endpoints were analyzed. | Drug: NOMAC-E2 COC | Contraception | 3,055 | 2024-01-12actual | — | 2025-11-21 |
| A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck RegionNCT05789576results2024-08-09Percentage of Participants Who Achieve a Target Lesion Physician Global Assessment (PGA) Score in the Head and Neck Region of Clear (0) or Almost Clear (1) With a ≥ 2-grade ImprovementOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: VTAMA (tapinarof) cream, 1% | Psoriasis | 31 | 2023-06-30actual | — | 2025-06-12 |
| A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque PsoriasisNCT05680740results2024-07-08Percentage of Participants Who Achieve an Intertriginous PGA (iPGA) Score of Clear (0) or Almost Clear (1) With a ≥ 2-grade ImprovementOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: VTAMA® (tapinarof) Cream 1% | Psoriasis | 34 | 2023-05-18actual | — | 2025-06-12 |
| Tapinarof for the Treatment of Atopic Dermatitis in Children and AdultsNCT05014568results2025-09-04Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: tapinarof cream, 1%, Vehicle cream | Atopic Dermatitis | 407 | 2023-03-30actual | — | 2025-09-04 |
| Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)NCT05032859results2025-09-02Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: tapinarof cream, 1%, vehicle cream | Atopic Dermatitis | 406 | 2023-02-03actual | — | 2025-09-02 |
| Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic DermatitisNCT05186805results2025-09-05Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tapinarof cream, 1% | Atopic Dermatitis | 36 | 2022-08-24actual | — | 2025-09-05 |
| Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)NCT04053387results2022-08-08Number of Subjects With Adverse Events and Serious Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: tapinarof cream, 1% | Plaque Psoriasis | 763 | 2021-04-06actual | — | 2025-08-06 |
| Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)NCT03768427results2023-02-08Percent Change From Baseline in LDL-C at Week 12Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Combination product: EZ 10 mg/Ator 10 mg, EZ 10 mg/Ator 20 mg · Drug: Atorvastatin, Placebo for FDC EZ/Ator, Placebo for atorvastatin | Hypercholesterolemia | 454 | 2021-03-17actual | — | 2024-05-16 |
| Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)NCT03956355results2022-10-13Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple ImputationRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tapinarof, Vehicle Cream | Plaque Psoriasis | 510 | 2020-05-26actual | — | 2025-06-12 |
| Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)NCT03983980results2022-10-13Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple ImputationRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tapinarof, Vehicle Cream | Plaque Psoriasis | 515 | 2020-05-13actual | — | 2025-06-12 |
| Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)NCT03019575results2021-04-08Change From Baseline in Log-Transformed Testicular Volume (TV) to Week 64Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Corifollitropin alfa, hCG | Hypogonadotropic Hypogonadism | 17 | 2020-05-05actual | — | 2024-05-23 |
| Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque PsoriasisNCT04042103results2022-05-06Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tapinarof cream, 1% | Plaque Psoriasis | 21 | 2020-01-09actual | — | 2025-06-19 |
| Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)NCT01327638observationalNumber of patients with Characteristics of inflammatory SPA/AS | — | Completed | Drug: etoricoxib, Other COX-2 inhibitor, nsNSAIDs | Spondylarthropathies; Spondylitis, Ankylosing | 21,108 | 2018-09-24actual | — | 2024-05-10 |
| An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)NCT01498770observationalFrequency and Proportion of Use, by Psychiatric Diagnosis, Among Asenapine and Aripiprazole Participants Aged 18 or Greater | — | Completed | Drug: Asenapine, Aripiprazole, Quetiapine, Risperidone, Olanzapine, Ziprasidone, Iloperidone, Paliperidone, Lurasidone, Clozapine, Amisulpride, Sertindole, Zotepine | Bipolar Disorder | 42 | 2017-12-21actual | — | 2022-02-04 |
| Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)NCT01495741observationalNumber of Participants with Bipolar Disorder with Identified and Potential Clinically Important Risks | — | Completed | — | Bipolar Disorder, Schizophrenia | 42 | 2017-12-18actual | — | 2022-02-04 |
| A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)NCT02748057results2018-12-04Percentage of Participants Who Experience at Least 1 Adverse Event (AE)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ezetimibe, Rosuvastatin | Hypercholesterolemia, Familial Hypercholesterolemia | 135 | 2017-12-11actual | — | 2024-05-16 |
| Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)NCT02741271results2019-05-22Change From Baseline in Morning (AM) Post-Dose % Predicted Forced Expiratory Volume in One Second (FEV1) in the Area Under the Curve (AUC)0-60Randomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: MF MDI 100 mcg BID (Open Label), MF/F MDI 100/10 mcg BID, MF MDI 100 mcg BID, Albuterol/Salbutamol PRN, Prednisone/Prednisolone | Asthma | 181 | 2017-12-04actual | — | 2024-05-16 |
| Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).NCT01703520observationalStage 1 - Person-Years of Exposure to Finasteride by Participant Age and Year | — | Completed | — | Male Breast Cancer | 575,216 | 2017-11-30actual | — | 2024-05-10 |
| A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)NCT02741245results2018-03-09Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C)Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ezetimibe 10 mg, Rosuvastatin 2.5 mg, Placebo for Ezetimibe, Placebo for Rosuvastatin | Hypercholesterolemia | 321 | 2017-01-18actual | — | 2024-05-16 |
| A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)NCT02460159results2018-01-11Percentage of Participants Who Experience 1 or More Adverse Event (AE)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: EZ 10 mg/Atorva 20 mg FDC, EZ 10 mg/Atorva 10 mg FDC | Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia | 135 | 2016-12-22actual | — | 2024-05-16 |
| A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)NCT01471340results2018-01-05Time-to-First Serious Asthma Outcomes (SAO): Number of First SAO in the MF/F vs MF ArmsRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg, Mometasone Furoate/Formoterol MDI 200/5 mcg, Mometasone Furoate MDI 100 mcg, Mometasone Furoate MDI 200 mcg, Albuterol 90 mcg /salbutamol 100 mcg HFA MDI, Prednisone/prednisolone | Asthma | 11,744 | 2016-11-30actual | — | 2024-05-23 |
| A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)NCT01408615observationalNumber of Oocytes Retrieved | — | Completed | Drug: corifollitropin alfa | Infertility, Female | 472 | 2016-11-18actual | — | 2022-02-03 |
| Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)NCT02616146results2019-01-18Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index)Randomized · Open-label · Prevention | Phase 3 | Terminatedsponsor's stated reason: Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy. | Drug: ENG-E2 125 μg/300 μg vaginal ring, LNG-EE 150 μg/30 μg COC | Contraception | 2,016 | 2016-10-06actual | — | 2024-05-17 |
| Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Risk for Pregnancy (MK-8342B-061)NCT02524288results2017-09-25Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index)Open-label · Prevention | Phase 3 | Terminatedsponsor's stated reason: This study was terminated by the Sponsor due to a business decision to discontinue product development for reasons unrelated to safety or efficacy outcomes. | Drug: ENG-E2 125 μg/300 μg vaginal ring | Contraception | 1,941 | 2016-09-16actual | — | 2024-05-17 |
| Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in the Treatment of Women With Primary Dysmenorrhea (MK-8342B-060)NCT02668822results2017-11-08Percentage of Participants With ≥3 Point Reduction in Peak Pelvic Pain Score and no Increase in Number of Ibuprofen Tablets Taken at Treatment Cycle 2, Compared to BaselineRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy. | Drug: ENG 125 μg + E2 300 μg vaginal ring (MK-8342B), Placebo vaginal ring, Ibuprofen | Dysmenorrhea | 18 | 2016-09-12actual | — | 2024-05-28 |
| Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)NCT02668783results2017-11-14Percentage of Participants With ≥3 Point Reduction in Peak Pelvic Pain Score and no Increase in Number of Ibuprofen Tablets Taken at Treatment Cycle 2, Compared to Baseline.Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy. | Drug: Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring, Placebo vaginal ring, Ibuprofen | Moderate to Severe Primary Dysmenorrhea | 25 | 2016-09-07actual | — | 2024-05-28 |
| A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)NCT02550288results2017-06-21Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Ezetimibe 10 mg, Atorvastatin 10 mg, Placebo for Ezetimibe 10 mg tablet, Placebo for Atorvastatin 10 mg capsule · Behavioral: Diet control/Daily Exercise | Hypercholesterolemia | 309 | 2016-05-30actual | — | 2024-05-16 |
| Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)NCT01077843observationalIncidence rate of gastrointestinal ulcer, perforation or bleeding | — | Completed | Drug: Etoricoxib, Other Cox-2 inhibitors, Other Non-selective NSAIDs · Other: No anti-inflammatory treatment | Ankylosing Spondylitis | 27,381 | 2015-07-01actual | — | 2022-02-18 |
| An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)NCT01599494Number of Cumulus-Oocyte-Complexes Retrieved During Oocyte Pick-upRandomized · Open-label · Treatment | Phase 3 | Withdrawn | Drug: MK-8962, recFSH, Ganirelix, human Chorionic Gonadotropin (hCG), Progesterone | Infertility | 0 | May 2015 | — | 2022-02-03 |
| Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)NCT01723579Number of In-treatment PregnanciesOpen-label · Treatment | Phase 3 | Withdrawn | Drug: Nomegestrol acetate (NOMAC), Estradiol (E2) | Contraception | 0 | May 2015 | — | 2022-02-16 |
| Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)NCT02320396results2016-05-30Change From Baseline in Total Nasal Symptom Score (TNSS) During 2 Weeks of TherapyRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Desloratadine 5 mg, Placebo | Seasonal Allergic Rhinitis | 449 | 2015-04-27actual | — | 2024-05-17 |
| Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)NCT01142596results2016-05-18Percentage of Participants in Categories of Change in Weight From Study P06124 Baseline to Final AssessmentRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine, Placebo | Schizophrenia | 201 | 2015-04-22actual | — | 2024-05-28 |
| Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063)NCT02275546results2016-04-28Percentage of Participants With Successful Ring InsertionRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Placebo vaginal ring · Device: Single-use, non-sterile applicator | Contraception: Optional Applicator for Insertion of Vaginal Ring | 164 | 2015-04-10actual | — | 2024-05-17 |
| A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)NCT01709331results2016-05-09Change From Baseline in Log-Transformed Testicular Volume at Week 52Open-label · Treatment | Phase 3 | Completed | Drug: Corifollitropin alfa, hCG | Hypogonadism, Hypogonadotropic Hypogonadism | 18 | 2015-04-08actual | — | 2024-05-24 |
| Cozaar XQ Re-examination Study (MK-0954-349)NCT01041807observationalNumber of participants with any adverse experience | — | Completed | Drug: amlodipine/losartan | Hypertension | 669 | Mar 2015actual | — | 2022-02-15 |
| A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)NCT01572675results2016-05-25observationalNumber of Participants Demonstrating Proper Use of Arcoxia® and Celebrex® | — | Completed | Drug: etorocoxib, celecoxib | Osteoarthritis | 547 | Mar 2015actual | — | 2022-02-09 |
| Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)NCT01685424observationalDose of Initial Etoricoxib Prescription | — | Completed | Drug: Etoricoxib | Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Gout, Arthritis | 79,189 | 2015-03-01actual | — | 2022-02-18 |
| A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)NCT01502371results2015-10-06Change From Baseline in Percent Predicted Morning (AM) Forced Expiratory Volume in 1 Second (FEV1) - MF MDI vs. PlaceboRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg, Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg, Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg, Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg, Placebo Metered Dose Inhaler (MDI), Placebo Dry Powder Inhaler (DPI) | Asthma | 583 | 2015-01-29actual | — | 2024-06-17 |
| A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic DermatitisNCT02094235Pharmacokinetics of E6005Randomized · Double-masked · Treatment | Phase 1/2 | Completed | Drug: E6005 0.05%, Placebo, E6005 0.2% | Atopic Dermatitis | 62 | Dec 2014actual | — | 2025-06-04 |
| The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)NCT01980940results2015-12-11Study Part 1: Maximum Concentration (Cmax) of ETOR After Single DosingRandomized · Double-masked · Treatment | Phase 1/2 | Completed | Drug: Etoricoxib 75 mg 4% DMSO Gel, Etoricoxib 75 mg 4% PG Gel, Etoricoxib 150 mg 4% DMSO Gel, Etoricoxib 150 mg 4% PG Gel, Etoricoxib 163 mg 4% DMSO gel, Placebo, Etoricoxib 50 mg 4% DMSO, Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel | Osteoarthritis Pain | 70 | 2014-11-26actual | — | 2024-06-27 |
| A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)NCT01208207results2015-07-02Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. NaproxenRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Part I - etoricoxib 60 mg, Part I - etoricoxib 90 mg, Part I- naproxen 1000 mg, Part I - Placebo to naproxen 500 mg, Part II- etoricoxib 60 mg, Part II- etoricoxib 90 mg, Part II- naproxen 1000 mg, Part I - Placebo to etoricoxib 60 mg, Part I - Placebo to etoricoxib 90 mg, Part II- Placebo to etoricoxib 60 mg, Part II - Placebo to etoricoxib 90 mg, Part II- Placebo to naproxen 500 mg | Spondylitis, Ankylosing | 1,015 | 2014-11-12actual | — | 2024-06-18 |
| IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)NCT00202878results2015-09-30Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe/simvastatin, simvastatin, Placebo for simvastatin 40 mg, Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Hypercholesterolemia, Myocardial Infarction | 18,144 | 2014-09-18actual | — | 2024-06-18 |
| A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)NCT01414192results2016-01-08observationalRate of Cardiovascular (CV) Events | — | Completed | — | Dyslipidemia, Hypercholesterolemia | 3,215 | 2014-09-15actual | — | 2024-09-05 |
| Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)NCT01349907results2015-03-09Number of Participants Who Experienced Clinical or Laboratory Adverse EventsNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Asenapine, Rescue medication | Bipolar Disorder | 322 | 2014-09-05actual | — | 2024-05-22 |
| Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)NCT01244828results2015-08-26Change From Baseline in Weight at Week 52Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Asenapine | Schizophrenia | 157 | 2014-08-21actual | — | 2024-05-28 |
| A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)NCT01617187results2015-08-31Change From Baseline in PANSS Total Score at Day 42Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine | Schizophrenia | 360 | 2014-08-11actual | — | 2024-06-18 |
| A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)NCT01208181results2015-05-21Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Etoricoxib 60 mg, Etoricoxib 90 mg, Placebo to Etoricoxib 60 mg, Placebo to Etoricoxib 90 mg | Arthritis, Rheumatoid | 1,404 | 2014-06-09actual | — | 2024-06-18 |
| A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)NCT01587235Number of Participants who Achieve Low-density Lipoprotein Cholesterol (LDL-C) goal (High-risk <100 mg/dL; Moderate-high and High risk <130 mg/dL)Randomized · Open-label · Treatment | Phase 4 | Withdrawn | Drug: Ezetimibe/simvastatin, Other Statin | Dyslipidemia | 0 | May 2014 | — | 2022-02-18 |
| Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)NCT00764478results2015-04-24Change From Baseline in Young Mania Rating Scale (Y-MRS) Total Score at Day 21Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine, Asenapine, Placebo | Bipolar 1 Disorder | 367 | 2014-04-30actual | — | 2024-06-18 |
| 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)NCT01098110results2015-04-17Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Asenapine 5 mg, Asenapine 10 mg, Placebo | Schizophrenia | 532 | 2014-04-14actual | — | 2024-06-20 |
| Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)NCT01916980results2014-11-19Change From Baseline in Pruritus/Itch Score (Sum of Daytime and Nighttime Scores) Assessed by the Investigator at Week 2Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Desloratadine 5 mg | Eczema, Dermatitis, Dermal Pruritus | 94 | 2014-03-08actual | — | 2024-06-18 |
| An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)NCT01916967results2014-10-30Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Desloratadine, Placebo | Urticaria | 239 | 2014-02-28actual | — | 2024-06-18 |
| Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)NCT01656434results2015-03-17Number of In-Treatment Pregnancies Per 100 Woman Years of Exposure (Pearl Index)Randomized · Open-label · Prevention | Phase 3 | Terminatedsponsor's stated reason: Business reasons | Drug: NOMAC-E2, NETA-EE, ethinylestradiol (EE), ferrous fumarate · Other: Placebo | Contraception | 3,173 | 2014-02-12actual | — | 2024-06-20 |
| A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)NCT01918033results2014-08-15Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Desloratadine 5 mg, Placebo | Perennial Allergic Rhinitis | 608 | 2014-01-26actual | — | 2024-06-18 |
| A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)NCT01611883results2014-12-17Change in Glycated Hemoglobin (HbA1c) From BaselineRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Ezetimibe, Placebo | Hypercholesterolemia | 152 | 2014-01-16actual | — | 2024-05-24 |
| Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115)NCT01026870Change from Baseline to Endpoint in the morning (AM trough) forced expiratory volume in 1 second (FEV1)Randomized · Quadruple-masked · Treatment | Phase 3 | Withdrawn | Drug: SCH 32088 mometasone furoate (MF) metered-dose inhaler, Placebo metered-dose inhaler BID | Asthma | 0 | Dec 2013 | — | 2022-02-16 |
| Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)NCT01852812results2014-09-29Percentage of Participants Who Experience at Least One Adverse Event (AE)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Montelukast Oral Granules (OG), Montelukast Chewable Tablets (CT) | Perennial Allergic Rhinitis | 87 | 2013-12-24actual | — | 2024-06-18 |
| A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)NCT01709318results2019-12-05Percentage of Participants With Ovulation Incidence, by CycleRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Nomegestrol acetate (NOMAC), Etonogestrel (ENG), Ethinyl estradiol (EE), Estradiol (E2) | Contraception | 666 | 2013-10-22actual | — | 2024-05-28 |
| Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)NCT01190267results2014-08-06Number of Participants With a Treatment-Emergent Adverse Event (AE) During Extension StudyOpen-label · Treatment | Phase 3 | Completed | Drug: asenapine | Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated | 204 | 2013-10-07actual | — | 2024-05-22 |
| Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)NCT01615874Change from Baseline in Plasma Cortisol Area Under the Curve (AUC) 0-24 hrsRandomized · Single-masked · Treatment | Phase 2 | Withdrawn | Drug: MF/F Metered Dose Inhaler (MDI) 25/5 mcg, MF/F MDI 50/5 mcg, MF/F MDI 100/5 mcg, BDP hydrofluoroalkane (HFA) 80 mcg, Montelukast tablets 5 mg (4 mg for children 5 years of age), Rescue medication: short-acting beta-2 agonist (SABA) MDI, Rescue medication: Prednisone/Prednisolone | Asthma | 0 | Sep 2013 | — | 2022-02-16 |
| A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)NCT01277211results2014-09-15Pearl Index, by Treatment GroupRandomized · Open-label · Prevention | Phase 3 | Completed | Drug: ENG 120 µg + EE 15 µg intravaginal ring, DRSP 3 mg + EE 30 µg | Contraception | 983 | 2013-09-18actual | — | 2024-06-20 |
| A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)NCT01670656results2017-08-24Change From Baseline in Mean Menstrual Cramping Pain Score Through Cycle 2Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR), Etonogestrel containing contraceptive vaginal ring (ENG-CVR), Placebo, Ibuprofen | Dysmenorrhea | 439 | 2013-09-11actual | — | 2024-05-28 |
| Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)NCT01857063results2014-05-26Change From Baseline in Total Nasal Symptom Score (TNSS) Averaged During 3 Hours of ExposureRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Montelukast, Placebo | Seasonal Allergic Rhinitis | 220 | 2013-09-01actual | — | 2024-06-17 |
| Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)NCT01244815results2014-09-04Change From Baseline in Y-MRS Total Score at Day 21Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: asenapine, Placebo to match asenapine, Rescue medication | Bipolar Disorder, Pediatric | 404 | 2013-08-28actual | — | 2024-06-20 |
| Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)NCT01146418results2016-02-03Percentage of Participants With ≥1 Vital Pregnancy (Cumulative Vital Pregnancy Rate)Randomized · Quadruple-masked · Other | Phase 3 | Completed | Biological: Corifollitropin alfa, recFSH (follitropin beta) | Infertility | 307 | 2013-07-24actual | — | 2024-06-20 |
| Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)NCT01277822results2014-04-24Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Losartan (+) amlodipine, Placebo to match losartan/amlodipine tablets, Amlodipine camsylate, Placebo to match amlodipine | Hypertension | 334 | 2013-04-22actual | — | 2024-06-20 |
| Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With OsteoarthritisNCT01554163results2013-12-04Time-Weighted Mean Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain SubscaleRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Etoricoxib 30 mg, Celecoxib 200 mg | Osteoarthritis of the Knee | 239 | Mar 2013actual | — | 2022-02-09 |
| Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)NCT01190254results2014-06-06Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: asenapine 2.5 mg, asenapine 5.0 mg, placebo | Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated | 306 | 2013-03-10actual | — | 2024-05-21 |
| An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial (MK-0653A-043-10)NCT01077830results2014-02-04observationalCrude Rate of Newly Diagnosed Cancer-Follow-up Primary Cohort | — | Completed | — | Cancer | 1,392 | Feb 2013actual | — | 2022-02-09 |
| A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)NCT01386125results2013-12-19Change From Baseline in Congestion/Obstruction ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mometasone Furoate Nasal Spray (MFNS), Placebo for MFNS | Nasal Polyps | 748 | Feb 2013actual | — | 2024-05-21 |
| Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)NCT01436253results2014-01-22observationalPercentage of Participants Achieving Target Lipid Values | — | Completed | Behavioral: Lifestyle Changes · Drug: Hypolipemics | Dyslipidemia | 2,196 | Feb 2013actual | — | 2022-02-09 |
| Survey of Osteoarthritis Real World Therapies (MK-0663-140)NCT01294696results2014-03-04observationalPercentage of Participants Who Reported Adequate vs. Inadequate Pain Relief at Baseline | — | Completed | Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Osteoarthritis | 1,261 | Jan 2013actual | — | 2024-08-29 |
| A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)NCT01350934results2014-07-22Base Study: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 6Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus), Calcitriol · Dietary supplement: Calcium 500 mg | Osteoporosis, Postmenopausal | 219 | 2013-01-10actual | — | 2024-06-20 |
| A Study of E6005 in Japanese Patients With Atopic DermatitisNCT01179880Pharmacokinetic parameter Cmax will be calculatedRandomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: E6005, Placebo | Atopic Dermatitis | 40 | Dec 2012actual | — | 2025-06-04 |
| Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)NCT01437111results2014-01-22Number of Participants With Serum 25-hydroxyvitamin D >=50 ng/mL at Week 26Open-label · Treatment | Phase 3 | Completed | Drug: MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet | Osteoporosis | 200 | 2012-12-05actual | — | 2024-04-22 |
| Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)NCT01490190results2014-01-14Number of Participants With Regular Menstrual CyclesOpen-label · Prevention | Phase 4 | Completed | Drug: Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing) | Contraception | 252 | 2012-12-05actual | — | 2024-05-24 |
| A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)NCT01307033results2014-01-06Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK-0954A, MK-954H, Placebo to MK-0954A, Placebo to MK-954H | Hypertension | 278 | 2012-12-04actual | — | 2024-05-17 |
| A Phase 2 Study of E6005 in Patients With Atopic DermatitisNCT01461941Changes of pruritus score from baselineRandomized · Single-masked · Treatment | Phase 2 | Completed | Drug: E6005, E6005 ointment (vehicle) | Atopic Dermatitis | 78 | Nov 2012actual | — | 2025-06-03 |
| Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)NCT00903721observationalEstimate the incidence of Adverse Drug Reactions (ADRs) | — | Completed | Drug: mometasone furoate | Allergic Rhinitis | 3,806 | Oct 2012actual | — | 2022-02-16 |
| Evaluation of Participant Responses to Educational Counseling About Different Combined Hormonal Contraceptive Choices (P06557)NCT01181778results2013-09-24observationalNumber of Participants Choosing Each Hormonal Contraceptive Method Before and After Counseling | — | Completed | — | Contraception | 1,919 | Oct 2012actual | — | 2022-02-04 |
| A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)NCT01673620results2014-11-14Number of Participants Experiencing at Least One Adverse Event (AE)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Montelukast 10 mg/loratadine 10 mg, Placebo | Allergic Rhinitis | 69 | 2012-10-10actual | — | 2024-09-04 |
| MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)NCT01154036results2014-02-12Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe 10 mg, atorvastatin, Comparator: rosuvastatin | Hypercholesterolemia | 1,547 | Sep 2012actual | — | 2022-02-09 |
| Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)NCT01566149results2013-07-29Number of Participants With At Least One Adverse Event (AE)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI, Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI | Asthma | 49 | Sep 2012actual | — | 2024-05-24 |
| A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)NCT01429168Mean Time to Loss of Efficacy in the Double Blind Withdrawal Period (Part 2)Randomized · Double-masked · Treatment | Phase 4 | Withdrawn | Drug: Etoricoxib, Placebo for etoricoxib | Osteoarthritis | 0 | Aug 2012 | — | 2022-02-18 |
| Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)NCT00756938results2014-03-03Mean Change From Baseline in Systolic Blood PressureRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: losartan potassium | Hypertension | 101 | 2012-08-14actual | — | 2024-06-18 |
| Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)NCT01462370results2013-07-10Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial DoseRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Etoricoxib, Ibuprofen, Placebo to etoricoxib, Placebo to ibuprofen, Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg | Dysmenorrhea | 139 | Jun 2012actual | — | 2022-02-09 |
| A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)NCT01370603results2013-07-10Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of TreatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Atorvastatin, Ezetimibe, Ezetimibe/atorvastatin, Placebo to atorvastatin, Placebo to ezetimibe, Placebo to ezetimibe/atorvastatin | Hypercholesterolemia | 328 | May 2012actual | — | 2022-02-09 |
| A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)NCT01333436results2013-04-09Postprandial Incremental Area Under the Curve From 0-6 Hours (iAUC)[0-6] of Apolipoprotein B-48 (ApoB-48)Non-randomized · Open-label · Diagnostic | Not applicable | Completed | Other: Test Meal | Dyslipidemia, Hypercholesterolemia | 93 | 2012-05-12actual | — | 2024-05-13 |
| A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)NCT01370590results2013-08-05Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of TreatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Atorvastatin, Ezetimibe, Ezetimibe/atorvastatin, Placebo to atorvastatin, Placebo to ezetimibe, Placebo to ezetimibe/atorvastatin | Hypercholesterolemia | 406 | Apr 2012actual | — | 2022-02-09 |
| Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)NCT00867165results2013-05-30Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe, Placebo | Primary Hypercholesterolemia | 138 | 2012-04-13actual | — | 2024-05-21 |
| Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)NCT01077817results2013-05-01observationalPercentage of Participants With Exposure to Study Drugs (Case-Cohort Analysis) | — | Completed | Drug: Alendronate, Etidronate, Ibandronate, Risedronate, Raloxifene | Esophageal Cancer, Squamous Cell Carcinoma, Adenocarcinoma | 684,815 | 2012-02-16actual | — | 2022-02-03 |
| MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)NCT01307046results2013-03-22Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK-0954A, Losartan, Placebo to MK-0954A, Placebo to losartan 100 mg, Placebo to losartan 50 mg | Hypertension | 336 | 2012-02-07actual | — | 2024-05-17 |
| A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)NCT01236430Area under the concentration-time-curve from time zero to infinity (AUC0-∞) of atorvastatinRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ezetimibe, Ezetimibe/atorvastatin 10mg/10mg FDC, Atorvastatin 10mg, Atorvastatin 80mg, Ezetimibe/atorvastatin 10mg/80mg FDC | Hyperlipidemia | 200 | Nov 2011actual | — | 2022-02-16 |
| Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)NCT01140048results2012-10-05observationalPercentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor | — | Completed | — | Respiratory Syncytial Virus Bronchiolitis | 343 | Oct 2011actual | — | 2022-02-02 |
| A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)NCT01258803results2013-07-18Area Under the Curve From 0-12 Hours (AUC[0-12h]) of the Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) After a Single Dose of MF/F MDI With Spacer Compared to Placebo MDI Combined With or Without SpacerRandomized · Single-masked · Treatment | Phase 2 | Completed | Drug: Formoterol Fumarate DPI, Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer, Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer, Placebo MDI with spacer, Placebo MDI without spacer, Mometasone Furoate DPI | Asthma | 92 | Oct 2011actual | — | 2024-05-23 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)NCT01206517results2012-12-21Maximum Plasma Concentration (Cmax) of AsenapineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Asenapine 2.5 mg, Asenapine 5 mg, Asenapine 10 mg | Schizophrenia, Bipolar I Disorder | 30 | 2011-08-04actual | — | 2024-05-23 |
| Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)NCT01144416results2012-12-27Percentage of Participants With a Vital PregnancyRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: SCH 900962 / Corifollitropin alfa / Org 36286, RecFSH / follitropin beta · Drug: Placebo for SCH 900962, Placebo for recFSH | Infertility | 1,424 | Jul 2011actual | — | 2022-02-03 |
| A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)NCT01001234results2012-05-08Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of AgeRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: rizatriptan, placebo, rizatriptan, placebo | Migraine, Acute | 1,382 | 2011-04-21actual | — | 2024-05-07 |
| A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)NCT01004263results2012-05-04Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any DoseOpen-label · Treatment | Phase 3 | Completed | Drug: rizatriptan benzoate | Acute Migraine With or Without Aura in Adolescents | 674 | 2011-04-18actual | — | 2024-04-22 |
| Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)NCT00862251results2012-03-16Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe (+) simvastatin, simvastatin 40 mg or atorvastatin 20 mg, Rosuvastatin, atorvastatin 10 mg or simvastatin 20 mg | Cardiovascular Disorder, Diabetes Mellitus | 808 | Mar 2011actual | — | 2024-05-16 |
| A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)NCT01165424results2012-01-23Number of Participants With Adverse Events and Adverse Drug ReactionsOpen-label · Treatment | Phase 3 | Completed | Drug: mometasone furoate | Rhinitis, Allergic, Perennial | 80 | Dec 2010actual | — | 2024-05-24 |
| Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)NCT01381679results2012-03-22observationalNumber of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level | — | Completed | Drug: Ezetimibe | Hypercholesterolemia | 1,682 | Dec 2010actual | — | 2022-02-09 |
| Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)NCT00820027results2020-04-07Average Change From Baseline for Pain Intensity at Rest Over Days 1 to 3 (Etoricoxib vs. Placebo)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Etoricoxib 90 mg, Etoricoxib 120 mg, Ibuprofen 600 mg, Matching Placebo for Etoricoxib 120 mg, Matching Placebo for Etoricoxib 90 mg, Matching Placebo for Ibuprofen, Morphine, Oxycodone | Pain, Postoperative | 776 | 2010-12-13actual | — | 2022-02-09 |
| An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)NCT00967746The primary efficacy outcome for the trial is insertion and removal characteristics, adverse event reporting and subject's satisfaction with the ENG-MIUSRandomized · Single-masked · Prevention | Phase 2 | Completed | Drug: Etonogestrel-releasing IUS, Etonogestrel-releasing IUS, Etonogestrel-releasing IUS · Device: Multiload-cu 375® | Contraception | 84 | Nov 2010actual | — | 2026-04-08 |
| A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)NCT00620035results2011-10-31Percentage of Applicator Users Who Were Very Satisfied and Satisfied- User Satisfaction Questionnaire for Domain: Design & Technical AspectsOpen-label · Prevention | Phase 3 | Completed | Drug: Radiopaque Etonogestrel Implant | Contraception | 301 | Oct 2010actual | — | 2022-02-04 |
| Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)NCT01135134results2011-11-03Change From Baseline in the Total Nasal Symptom Score at 2 WeeksRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate, Placebo | Rhinitis, Allergic, Perennial | 333 | Oct 2010actual | — | 2024-05-28 |
| Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)NCT00782184results2011-10-31Percent Change From Baseline in Low Density Lipoprotein (LDL)-CRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe/simvastatin 10/40, atorvastatin 40 mg, atorvastatin 20 mg | Hypercholesterolemia | 250 | Sep 2010actual | — | 2024-05-16 |
| Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)NCT00604812results2009-09-02Safety and Tolerability of Single Doses of Rizatriptan in Pediatric MigraineursRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: rizatriptan benzoate (5 mg), rizatriptan benzoate (10 mg), Rizatriptan 5 mg Placebo, Rizatriptan 10 mg Placebo | Migraine Disorders | 31 | 2010-09-17actual | — | 2024-04-19 |
| Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)NCT01368185results2011-09-01observationalSerum Uric Acid (SUA) Level | — | Completed | — | Hypertension | 1,705 | Aug 2010actual | — | 2022-02-09 |
| A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)NCT01390415results2011-09-13observationalNumber of Participants With Macroalbuminuria After 6 Months of Treatment | — | Completed | — | Hypertension | 136 | Aug 2010actual | — | 2022-02-09 |
| Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)NCT00383435results2011-10-03Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI, Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 1,055 | Jul 2010actual | — | 2024-05-20 |
| Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)NCT00383721results2011-10-26Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI, Placebo | Chronic Obstructive Pulmonary Disease (COPD) | 1,196 | Jul 2010actual | — | 2024-05-23 |
| A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)NCT00692913results2011-08-15Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 26Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol) · Dietary supplement: Calcium Supplement 500 mg · Other: Referred-Care Model | Osteoporosis | 515 | Jul 2010actual | — | 2024-05-09 |
| A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)NCT00788710results2011-07-22Average Pain Intensity at Rest Over Days 1 to 3Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: etoricoxib (MK0663) 120 mg, Comparator: Placebo, etoricoxib (MK0663) 90 mg | Acute Pain Following a Total Abdominal Hysterectomy | 430 | Jul 2010actual | — | 2022-02-09 |
| FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)NCT01065779results2011-09-13observationalNumber of Participants With Serious Adverse Events | — | Completed | Drug: FOSAMAX PLUS, FOSAMAX PLUS D | Osteoporosis | 880 | Jul 2010actual | — | 2022-02-03 |
| EZETROL® Re-examination Study (MK0653-175)(COMPLETED)NCT01070953results2011-11-04observationalParticipants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation | — | Completed | — | Hypercholesterolemia | 4,467 | Jul 2010actual | — | 2022-02-09 |
| Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)NCT01345786results2011-08-29Maximum Observed Plasma Concentration of NOMAC (Cmax of NOMAC)Randomized · Open-label · Prevention | Phase 1 | Completed | Drug: Commercial NOMAC-E2, Phase 3 NOMAC-E2 "Batch A", Phase 3 NOMAC-E2 "Batch B" | Healthy Postmenopausal Females | 158 | Jun 2010actual | — | 2022-02-09 |
| Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)NCT00671528results2011-06-16Percent Improvement of Individually Measured Signs of the DiseaseRandomized · Quadruple-masked · Treatment | Phase 4 | Terminatedsponsor's stated reason: terminated early due to lack of recruitment \[only 3 of 207 subjects were enrolled\] | Drug: Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate), Cream (betamethasone diproprionate and gentamicin), Cream (betamethasone diproprionate) | Dermatitis, Atopic, Eczema, Atopic, Skin Diseases, Eczematous | 3 | May 2010actual | — | 2022-02-09 |
| Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)NCT00761527results2012-03-01observationalNumber of Adverse Events Reported By Category After 14 Days of Treatment | — | Completed | Drug: Desloratadine Syrup | Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial, Urticaria | 2,980 | May 2010actual | — | 2022-02-09 |
| A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)NCT00783263results2011-09-14Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of TreatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Comparator: rosuvastatin 5 mg + ezetimibe 10 mg, Comparator: rosuvastatin 10 mg, Comparator: rosuvastatin 10 mg + ezetimibe 10 mg, Comparator: rosuvastatin 20 mg | Hypercholesterolemia | 440 | May 2010actual | — | 2024-05-14 |
| Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)NCT00871351results2011-08-23Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) ValuesRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Ezetimibe, Atorvastatin, Atorvastatin, Rosuvastatin | Primary Hypercholesterolemia | 125 | 2010-05-01actual | — | 2024-05-23 |
| Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)NCT00284856results2011-05-03Percentage of Asthma-control Days Over the 6-month Treatment PeriodRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: Placebo, Comparator: fluticasone, Comparator: Placebo | Asthma | 1,640 | Apr 2010actual | — | 2024-05-10 |
| Vytorin Reexamination Study (0653A-174)NCT01070966results2011-05-10observationalPercentage of Participants With Any Clinical and/or Laboratory Adverse Experiences While Taking VYTORIN® Within 14 Days After Treatment Discontinuation | — | Completed | — | Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) | 2,089 | Apr 2010actual | — | 2022-02-09 |
| The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)NCT00534976results2011-04-07Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours PostdoseRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Comparator: montelukast sodium, Comparator: Comparator: placebo (unspecified) | Exercise-induced Bronchoconstriction (EIB) | 364 | Mar 2010actual | — | 2024-05-13 |
| A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)NCT00894556results2011-01-20Pain Relief (PR)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: rizatriptan, Comparator: Placebo, Comparator: Sumatriptan | Acute Migraine | 109 | 2010-01-12actual | — | 2024-05-10 |
| Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (P05155)NCT00552032results2012-01-31Change From Baseline in Adenoid/Choana (A/C) Index GradeRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Mometasone Furoate nasal spray, Placebo | Adenoids Hypertrophy | 132 | 2010-01-01actual | — | 2024-05-20 |
| A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)NCT00705211observationalA primary endpoint is the incidence of adverse events. | — | Completed | Drug: Ezetimibe, Ezetimibe + other lipid-lowering medication(s) | Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia | 1,794 | Dec 2009actual | — | 2022-02-16 |
| Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)NCT00394355results2011-03-07Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD) From the Averaged Baseline Value to the Endpoint of Treatment Time PointRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: mometasone furoate dry powder inhaler, mometasone furoate dry powder inhaler, fluticasone propionate hydrofluoroalkane (HFA), montelukast | Asthma | 566 | Oct 2009actual | — | 2024-05-22 |
| Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED)NCT00553891To document the long-term effect of treatment with Nasonex in moderate to severe adenoids hypertrophy (which cause >50% obstruction of the posterior choanae). as reflected by the need for adenoidectomy within one year of the treatment regimen.Randomized · Double-masked · Treatment | Phase 4 | Withdrawnsponsor's stated reason: No enrollment because of war in the study country. | Drug: mometasone furoate nasal spray, placebo nasal spray | Nasal Obstruction, Adenoids Hypertrophy, Adenoidectomy | 0 | Oct 2009actual | — | 2022-02-18 |
| Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)NCT00702234results2015-04-27observationalPercentage of Women With Ongoing Pregnancy After a Corifollitropin Alfa COS Cycle in Base Study and ≥1 Live Born Infant During Follow-up (Live Birth Rate) | — | Completed | Biological: Corifollitropin alfa, GnRH antagonist, (rec)hCG, FSH · Drug: Progesterone | Pregnancy, Neonates | 268 | 2009-10-22actual | — | 2024-09-05 |
| A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine ProphylaxisNCT00812006results2011-01-27Pain Relief (PR)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: rizatriptan benzoate, Comparator: placebo | Migraine | 108 | 2009-10-22actual | — | 2024-05-23 |
| Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)NCT00687531results2011-07-20Forced Expiratory Volume in 1 Second (FEV1)Non-randomized · Open-label · Treatment | Phase 4 | Terminated | Drug: Mometasone Furoate | Asthma | 385 | Sep 2009actual | — | 2024-05-24 |
| A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)NCT00704444observationalIncidence of adverse events | — | Completed | Drug: Ezetimibe, Ezetimibe + other lipid-lowering medication(s) | Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia | 11,332 | Sep 2009actual | — | 2022-02-16 |
| LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)NCT00496834results2010-12-15Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study DrugRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: losartan potassium, Comparator: carvedilol, Comparator: losartan (+) hydrochlorothiazide (HCTZ), Comparator: carvedilol (+) hydrochlorothiazide | Hypertension | 201 | 2009-09-01actual | — | 2024-05-22 |
| Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367)NCT01098071results2011-11-29Severity of Nasal Obstruction Symptoms at Baseline and Week 12 as Measured by the Total Clinical ScoreOpen-label · Treatment | Phase 4 | Completed | Drug: mometasone furoate nasal spray | Adenoids | 34 | 2009-09-01actual | — | 2024-05-28 |
| Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)NCT00337675results2010-03-15Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment PeriodRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: Placebo (unspecified), montelukast sodium | Asthma | 1,771 | Aug 2009actual | — | 2024-05-10 |
| Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)NCT00730132results2010-10-11observationalPercentage of Patients Receiving Each Variant of Modified Lipid-lowering Therapy: Statin Dose Titration, Administration of a New Statin, Administration of a Ezetimibe in Addition to a Current Statin. | — | Completed | Drug: Ezetimibe, Statin | Coronary Heart Disease, Hypercholesterolemia | 712 | Aug 2009actual | — | 2022-02-09 |
| A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)NCT00442117results2011-02-10Mean Percent Change of Forced Expiratory Volume in One Second (FEV1) From Baseline to Week 12.Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: mometasone furoate dry powder inhaler, Budesonide DPI | Asthma | 180 | Jul 2009actual | — | 2024-05-20 |
| Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)NCT00654628results2010-08-26The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: ezetimibe (+) simvastatin | Hypercholesterolemia | 173 | 2009-07-01actual | — | 2024-05-22 |
| SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)NCT00739674results2010-08-11Number of Patients Achieving Target Blood Pressure at Week 14 From BaselineRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB]) · Behavioral: Low Salt Diet | Hypertension | 992 | 2009-07-01actual | — | 2024-05-16 |
| Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)NCT00511342results2011-08-29Mean Change From Baseline in Z-scores of the Lumbar Spine (L2-L4) and Femoral NeckRandomized · Open-label · Prevention | Phase 3 | Completed | Drug: NOMAC-E2, LNG-EE | Contraception | 110 | Jun 2009actual | — | 2022-02-09 |
| Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)NCT00635882results2011-02-09Mean Percent Change From Baseline to Day 14 in Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: mometasone furoate/formoterol 100/10 mcg, mometasone furoate/formoterol 200/10 mcg, mometasone furoate/formoterol 400/10 mcg, MF DPI 200 mcg, MF MDI 200 mcg, Placebo | Asthma, Airway Inflammation | 93 | Jun 2009actual | — | 2024-05-14 |
| Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)NCT00723723observationalpercentage of patients reaching target LDL levels | — | Completed | Drug: Statin | Coronary Heart Disease, Hypercholesterolemia, Hyperlipidemia | 555 | Jun 2009actual | — | 2022-02-16 |
| Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)NCT00653523results2010-06-30Number of Participants With Adverse Events and Adverse ReactionsNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Ezetimibe, Simvastatin | Hypercholesterolemia | 151 | 2009-06-01actual | — | 2024-05-21 |
| Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)NCT00654095results2010-10-05Number of Participants With Adverse Events and Adverse ReactionsNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Ezetimibe, atorvastatin | Hypercholesterolemia | 146 | 2009-06-01actual | — | 2024-05-21 |
| A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)NCT01431508results2011-11-22Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Losartan 50 mg / HCTZ 12.5 mg | Hypertension | 15 | 2009-06-01actual | — | 2024-05-22 |
| An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent AsthmaNCT00599027results2010-04-30The Change of the Rhinasthma Global Summary Score From Baseline to Endpoint After 28 Days of Treatment.Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate nasal spray (MFNS), Placebo nasal spray | Allergic Rhinitis, Asthma | 51 | May 2009actual | — | 2024-05-21 |
| Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)NCT00702273results2014-11-20observationalPercentage of Participants With an Ongoing Pregnancy (Cumulative Ongoing Pregnancy Rate) | — | Completed | Drug: 150 µg Corifollitropin Alfa, Placebo for Corifollitropin Alfa, Placebo for RecFSH/Follitropin beta, Ganirelix · Biological: 200 IU RecFSH/Follitropin beta (Days 1 to 7), 200 IU RecFSH/Follitropin beta (Days 8 to hCG), hCG, Progesterone | In Vitro Fertilization | 344 | 2009-05-19actual | — | 2024-09-05 |
| 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)NCT00174265results2010-07-05Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total ScoreNon-randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: asenapine, olanzapine | Schizophrenia | 196 | Apr 2009actual | — | 2022-02-09 |
| Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)NCT00536380results2010-05-03Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mgRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: 5-mg Desloratadine, 10-mg Desloratadine, 20-mg Desloratadine | Chronic Idiopathic Urticaria | 314 | Apr 2009actual | — | 2024-05-23 |
| Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)NCT00729651results2010-04-02Patients With Serum 25 OHD (Serum 25-hydroxyvitamin D) Below the Deficiency Level (Less Than 15 ng/ml) at 16 Weeks of TreatmentRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: alendronate sodium (+) cholecalciferol, Comparator: Alendronate sodium (Fosamax) · Dietary supplement: Comparator: Calcium | Osteoporosis Postmenopausal | 343 | 2009-04-10actual | — | 2024-04-23 |
| BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)NCT00546754results2010-04-13Change in Systolic Blood Pressure From Baseline to Week 12Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: losartan potassium (+) hydrochlorothiazide, Comparator: Valsartan (+) Hydrochlorothiazide | Hypertension | 808 | 2009-04-01actual | — | 2024-05-16 |
| Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)NCT00090259results2010-08-02Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart FailureRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Losartan 50 mg, Losartan 150 mg | Heart Failure | 3,834 | 2009-03-31actual | — | 2024-05-16 |
| A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)NCT00521599results2010-03-23Change From Baseline in the Average AM Peak Expiratory Flow (PEF) Over the 7 Days of Week 8.Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Mometasone furoate dry powder inhaler, Placebo | Asthma | 672 | Mar 2009actual | — | 2024-05-23 |
| A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)NCT00535405results2010-05-25Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Atorvastatin 10 mg, Ezetimibe 10 mg/simvastatin 20 mg, Atorvastatin 20 mg, Ezetimibe 10 mg/simvastatin 40 mg, Atorvastatin 40 mg | Hypercholesterolemia | 1,289 | Mar 2009actual | — | 2024-05-16 |
| Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPLETED)NCT00920361observationalNumber of retrieved oocytes | — | Completed | Drug: Follitropin beta | Fertilization in Vitro | 1,664 | Mar 2009actual | — | 2022-02-04 |
| Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED)NCT00920634observationalOccurrence of ovulation | — | Completed | Drug: Follitropin beta | Anovulation | 384 | Mar 2009actual | — | 2022-02-04 |
| Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)NCT01005056observationalNumber of participants who did not get pregnant during the study. | — | Completed | Drug: Ethinylestradiol + Desogestrel | Contraception | 3,838 | Mar 2009actual | — | 2022-02-04 |
| A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)NCT00620464results2010-05-17Bioequivalence of Implanon® and Radiopaque Implanon.Randomized · Quadruple-masked · Prevention | Phase 3 | Completed | Drug: Radiopaque Implanon, Implanon (etonogestrel implant) | Contraception | 108 | Feb 2009actual | — | 2022-02-04 |
| Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)NCT00666679results2010-02-03Change From Baseline in FEV1 (Forced Expiratory Volume; Volume of Air That is Exhaled During the First Second of a Forced Exhalation)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Comparator: mometasone, Comparator: montelukast, Comparator: placebo (unspecified) | Asthma | 134 | Feb 2009actual | — | 2024-05-10 |
| Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)NCT00696878results2015-04-23Percentage of Participants With Clinically Relevant ImmunogenicityOpen-label · Treatment | Phase 3 | Completed | Drug: Corifollitropin alfa, Progesterone · Biological: FSH, GnRH antagonist, (rec)hCG | In Vitro Fertilization | 682 | 2009-02-17actual | — | 2024-06-18 |
| Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)NCT00281320results2010-09-09Number of Participants Who Experienced an Adverse EventRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine | Psychosis | 122 | Dec 2008actual | — | 2022-02-09 |
| A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)NCT00694369results2010-01-29Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Comparator: etoricoxib, Comparator: ibuprofen, Comparator: acetaminophen + codeine, Comparator: placebo | Postoperative Dental Pain | 588 | Dec 2008actual | — | 2022-02-09 |
| Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)NCT00702546results2015-05-05observationalPercentage of Participants With an Ongoing Pregnancy (Cumulative Ongoing Pregnancy Rate) | — | Completed | Drug: corifollitropin alfa, gonadatropin releasing hormone (GnRH) antagonist ganirelix, human chorion gonadatropin (hCG), placebo-recFSH (follitropin alfa), placebo-corifollitropin alfa · Biological: recFSH (follitropin alfa), progesterone, open-label recFSH | In Vitro Fertilization | 102 | Dec 2008actual | — | 2022-02-03 |
| A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)NCT00725491results2010-01-22The Amount of International Units (IU) of Recombinant Follicle Stimulating Hormone (recFSH) Needed in a Controlled Ovarian Stimulation (COS) Cycle up to the First Day the Human Chorionic Gonadotropin (hCG) Criterion is Met.Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: ganirelix, triptorelin | Controlled Ovarian Stimulation | 259 | Dec 2008actual | — | 2022-02-03 |
| The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)NCT00739297results2010-04-09Change From Baseline in FEV1 Over 4 HoursRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Comparator: montelukast, Comparator: placebo | Chronic Asthma | 68 | Dec 2008actual | — | 2024-05-09 |
| Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)NCT00757627results2010-05-11The Percentage of Participants Achieving ≥30% Decrease From Baseline in Pain Intensity as Measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Question 1 "Pain Walking on a Flat Surface" at Week 4Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: etoricoxib | Pain | 500 | Dec 2008actual | — | 2022-02-09 |
| Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)NCT00127166results2009-12-03Maximum Post-exercise Percent (%) Fall in FEV1Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Montelukast sodium, Salmeterol xinafoate, Fluticasone propionate, Montelukast matching placebo, Salmeterol matching placebo | Exercise Induced Asthma | 154 | Nov 2008actual | — | 2024-05-10 |
| Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)NCT00145496results2010-03-25Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine, Olanzapine | Schizophrenia | 468 | Nov 2008actual | — | 2022-02-08 |
| Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)NCT00424008results2010-11-01The Area Under the Curve From 0 to 12 Hours [AUC](0-12 hr) of the Change From Baseline to the Week 12 Endpoint in Forced Expiratory Volume in One Second (FEV1)Randomized · Single-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate/formoterol (MF/F) MDI, Fluticasone propionate/salmeterol (F/SC) DPI | Asthma | 722 | Nov 2008actual | — | 2024-05-20 |
| Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)NCT00732381results2009-11-13The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 DaysRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate nasal spray (MFNS), Matching placebo nasal spray | Allergic Rhinitis | 351 | Nov 2008actual | — | 2024-05-21 |
| Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)NCT00779532Investigate whether once daily multiple therapeutic and supra-therapeutic doses of NOMAC-E2 prolong the mean QTcF interval at steady state to the threshold of regulatory concern compared to placeboRandomized · Triple-masked · Other | Phase 1 | Completed | Drug: Moxifloxacin, NOMAC-E2 (Org 10486-0 + Org 2317), Moxifloxacin placebo, NOMAC-E2 placebo | Contraception | 189 | Nov 2008actual | — | 2022-02-16 |
| Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)NCT00909389results2011-10-04observationalNumber of Participants Who Had an Adverse Event (AE). | — | Completed | Drug: Vytorin (R) (Ezetimibe + Simvastatin) | Hypercholesterolemia | 4,748 | Nov 2008actual | — | 2022-02-09 |
| EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)NCT00089895results2009-12-21Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Eptifibatide (Integrilin), Placebo | Myocardial Ischemia, Acute Coronary Syndrome | 9,406 | 2008-11-01actual | — | 2024-05-17 |
| A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)NCT00604500results2011-04-12Overall Discrepancy RateOpen-label · Treatment | Phase 3 | Completed | Drug: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ) | Asthma, COPD | 272 | 2008-11-01actual | — | 2024-05-20 |
| Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)NCT00418834results2009-10-06Percent Change From Baseline in LDL-C at Week 6Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe and atorvastatin, atorvastatin, Placebo (unspecified) | Hypercholesterolemia | 1,053 | Oct 2008actual | — | 2024-05-14 |
| Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)NCT00442897results2009-11-09Number of Participants Reaching the LDL-C (Low Density Lipoprotein-Cholesterol) Goal (< 100 mg/dl) After 6 Weeks of TreatmentRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: simvastatin (+) ezetimibe, Comparator: atorvastatin | Hypercholesterolemia | 229 | Oct 2008actual | — | 2024-05-22 |
| Exercise Induced Bronchoconstriction (0476-359)NCT00664937Ventilation volume by 3He MRI, ventilation volume defects by 3He MRI, pulmonary lung function by spirometerRandomized · Double-masked · Diagnostic | Phase 1 | Completed | Drug: montelukast sodium, Comparator: placebo (unspecified) | Asthma, Exercise-induced | 24 | Oct 2008actual | — | 2024-05-09 |
| Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)NCT00728416results2009-11-19Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 DaysRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate nasal spray (MFNS), Matching placebo nasal spray | Allergic Rhinitis | 333 | Oct 2008actual | — | 2022-02-09 |
| Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)NCT00733005results2009-11-19The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate nasal spray (MFNS), Matching placebo nasal spray | Allergic Rhinitis | 324 | Oct 2008actual | — | 2024-05-21 |
| Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)NCT00832455results2010-02-05Asthma Control Questionnaire (ACQ)Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: montelukast sodium | Asthma | 445 | Oct 2008actual | — | 2024-05-13 |
| Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)NCT00383240results2011-03-07Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F Versus MFRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID, Mometasone furoate MDI (MF MDI) 200 mcg, formoterol fumarate 10 mcg, Placebo | Asthma | 781 | Sep 2008actual | — | 2024-05-20 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)NCT00636207results2013-01-28Number of Participants Who Experienced At Least One Adverse EventRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Montelukast, Placebo | Asthma | 46 | Sep 2008actual | — | 2024-05-09 |
| Montelukast in Chronic AsthmaNCT00802789observationalDocumentation of asthma control via ACT (Asthma Control Test). | — | Completed | — | Asthma | 2,000 | Sep 2008actual | — | 2022-02-18 |
| An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))NCT00568178results2009-10-30Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Losartan Potassium, Comparator: amlodipine besylate, Enalapril Maleate · Other: Comparator: Placebo (Losartan), Comparator: Placebo (amlodipine besylate), Placebo (Losartan) | Proteinuria | 306 | 2008-09-01actual | — | 2024-05-23 |
| Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)NCT00383552results2011-10-25Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID, Mometasone Furoate MDI (MF MDI), Formoterol Fumarate 10 mcg, Placebo | Asthma | 746 | Aug 2008actual | — | 2024-05-17 |
| Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)NCT00413062results2011-08-29Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)Randomized · Open-label · Prevention | Phase 3 | Completed | Drug: NOMAC-E2, DRSP-EE | Contraception | 2,281 | Aug 2008actual | — | 2022-02-09 |
| A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)NCT00496730results2009-11-17Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks.Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: simvastatin (+) ezetimibe, Comparator: atorvastatin | Hypercholesterolemia | 256 | Aug 2008actual | — | 2024-05-16 |
| A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)NCT00651807The effect of Org 3236 on prostate volume compared to placeboRandomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business Reasons | Drug: etonogestrel, Placebo | Benign Prostatic Hyperplasia (BPH) | 16 | Aug 2008actual | — | 2026-04-08 |
| Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)NCT00724477results2010-02-26observationalNumber of Participants Reaching the Targeted LDL-C Levels | — | Completed | Drug: INEGY | Primary Hypercholesterolemia | 1,663 | Aug 2008actual | — | 2022-02-09 |
| Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)NCT00702338results2014-06-05observationalPercentage of Mothers With ≥1 Live Born Infant During Follow-up (Take-Home Baby Rate): Protocol Defined | — | Completed | Drug: corifollitropin alfa · Biological: recombinant Follicle Stimulating Hormone (recFSH), human Chorion Gonadotropin (hCG), hCG Bolus injection | Pregnancy, Neonates | 1 | 2008-08-09actual | — | 2024-09-05 |
| Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)NCT00409773results2009-08-04Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe (+) simvastatin, Comparator: atorvastatin calcium, Comparator: Placebo (unspecified) | Hypercholesterolemia, Metabolic Syndrome | 1,143 | Jul 2008actual | — | 2024-05-16 |
| Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)NCT00778999results2009-08-12Total Number of OocytesRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Marvelon | Infertility | 442 | 2008-07-24actual | — | 2022-02-04 |
| To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)NCT00150176results2010-05-28Time to Relapse or an Impending RelapseRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine - Open Label, Placebo - Double Blind, Asenapine - Double Blind | Schizophrenia | 831 | Jun 2008actual | — | 2022-02-08 |
| Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)NCT00378378results2010-07-20Change From Baseline 24-hour Urinary Free Cortisol LevelRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mometasone Furoate Nasal Spray (MFNS), Placebo nasal spray | Nasal Polyps | 127 | Jun 2008actual | — | 2024-05-20 |
| The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)NCT00423176results2010-06-22Baseline Change in AM/PM PRIOR Major Symptoms Score (Mss) Minus Sinus Headache Averaged Over Days 1 to 29.Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Based on business priorities. Not related to any safety or efficacy issue \& took place before data were unblinded or analyzed | Drug: MFNS and antibiotic, Matching Placebo nasal spray plus antibiotic | Sinusitis | 237 | Jun 2008actual | — | 2024-05-20 |
| A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)NCT00462748results2009-08-17Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at Study EndRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe (+) simvastatin, Comparator: atorvastatin, Comparator: rosuvastatin | Hypercholesterolemia | 786 | Jun 2008actual | — | 2024-05-16 |
| Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)NCT00723736results2009-08-06observationalProportion of Patients With Adverse Events | — | Completed | Drug: Desloratadine | Rhinitis, Urticaria | 100 | Jun 2008actual | — | 2022-02-09 |
| An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)NCT00092677results2009-05-27Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe (+) simvastatin, Comparator: Placebo | Aortic Stenosis | 1,873 | Apr 2008actual | — | 2024-05-16 |
| Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)NCT00405964results2010-11-19Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of TreatmentRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: 5-mg Desloratadine, Placebo tablet | Allergic Rhinitis | 716 | Apr 2008actual | — | 2024-05-20 |
| Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)NCT00702624results2015-04-30observationalPercentage of Women With ≥1 Live Born Infant During Follow-up (Take-Home Baby Rate) | — | Completed | Drug: Corifollitropin alfa, gonadatropin releasing hormone (GnRH) antagonist ganirelix, placebo-recFSH (follitropin beta), placebo-corifollitropin alfa · Biological: recFSH (follitropin beta), human chorion gonadotropin (hCG), progesterone, open-label recFSH (follitropin beta) | Pregnancy, Neonates | 113 | Apr 2008actual | — | 2022-02-03 |
| Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)NCT00704535results2009-07-14observationalSafety as Measured by Number of Subjects With at Least One Adverse Event | — | Completed | Drug: Ezetimibe | Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia | 4,105 | Apr 2008actual | — | 2022-02-09 |
| Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)NCT00703014results2014-11-24observationalNumber of Mothers in Current Follow Up Trial Experiencing Adverse Events (AEs) | — | Completed | Drug: Corifollitropin Alfa 150 μg, Placebo for Corifollitropin Alfa, Placebo for RecFSH/Follitropin beta, Ganirelix · Biological: 200 IU RecFSH/Follitropin beta (Days 1 to 7), 200 IU RecFSH/Follitropin beta (Days 8 to hCG), hCG, Progesterone | Pregnancy, Neonates | 541 | 2008-04-18actual | — | 2024-09-19 |
| Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)NCT00516737results2009-04-14Number of Participants Who Are Pain Free at 2 Hours Post-DoseRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Comparator: rizatriptan benzoate, Comparator: Placebo | Migraine | 207 | 2008-04-08actual | — | 2024-04-22 |
| A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)NCT00697255results2014-06-09Percentage of Participants With Monofollicular Response (Monofollicular Rate)Randomized · Open-label · Treatment | Phase 2 | Terminated | Drug: corifollitropin alfa · Biological: recombinant Follicle Stimulating Hormone (recFSH), human Chorion Gonadotropin (hCG), hCG Bolus injection | Ovulation Induction | 8 | 2008-04-03actual | — | 2024-06-17 |
| Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)NCT00511199results2011-08-29Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)Randomized · Open-label · Prevention | Phase 3 | Completed | Drug: NOMAC-E2, DRSP-EE | Contraception | 2,152 | 2008-04-01actual | — | 2022-02-09 |
| A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)NCT00117338results2009-08-11Improvement in FEV1 (Forced Expiratory Volume in 1 Second) Over the First 60 Minutes After AdministrationRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: placebo (unspecified) | Asthma | 276 | Mar 2008actual | — | 2024-05-10 |
| Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)NCT00264147results2009-07-07Proportion of Patients Who Met the ACR20 Responder Index CriteriaRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: etoricoxib, etoricoxib, etoricoxib, etoricoxib, Comparator: placebo, etoricoxib, Comparator: diclofenac | Rheumatoid Arthritis | 761 | Mar 2008actual | — | 2022-02-09 |
| A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)NCT00540839Percentage of days without asthmaRandomized · Triple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Based on input from regulatory agencies, it is not necessary to conduct this study. An ongoing study was sufficient for regulatory purposes. | Drug: Montelukast sodium, Placebo to montelukast, Fluticasone propionate, Placebo to fluticasone | Asthma, Bronchial | 0 | Mar 2008actual | — | 2022-02-14 |
| The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)NCT00423579results2009-08-25Change in Low-density-lipoprotein Cholesterol (LDL-C) at 6 WeeksRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Ezetimibe/Simvastatin 10/20 mg, simvastatin 40 mg | Hypercholesterolemia, Coronary Disease | 120 | 2008-03-01actual | — | 2024-05-22 |
| A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)NCT00479713results2009-06-10Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of TreatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe (+) simvastatin, Comparator : rosuvastatin calcium, Comparator: Placebo (unspecified), Comparator: Placebo (unspecified) | Hypercholesterolemia | 618 | 2008-03-01actual | — | 2024-05-16 |
| To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)NCT00271817results2009-08-03Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Comparator: ezetimibe/simvastatin + niacin (ER), Comparator: Placebo to ezetimibe/simvastatin, Comparator: niacin (ER) tablet, Comparator: ezetimibe (+) simvastatin, Comparator: Placebo to Niacin (ER), Comparator: ezetimibe/simvastatin and niacin (ER), Comparator: ezetimibe and simvastatin, Comparator: Placebo to niacin (ER) | Hypercholesterolemia | 1,220 | Feb 2008actual | — | 2024-05-16 |
| To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)NCT00276484results2009-04-13Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-CRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: atorvastatin, atorvastatin, ezetimibe | Hypercholesterolemia | 579 | Feb 2008actual | — | 2024-05-14 |
| Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)NCT00552110results2009-07-08Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15Randomized · Single-masked · Treatment | Phase 2 | Completed | Drug: OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY), OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY), mometasone furoate nasal spray (MFNS) once daily, oxymetazoline nasal spray (OXY) twice daily, Placebo | Seasonal Allergic Rhinitis | 707 | Feb 2008actual | — | 2024-05-14 |
| Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)NCT00739050results2010-12-16Change From Baseline in Endothelial Thickness After 12 Weeks of Treatment.Randomized · Double-masked · Treatment | Phase 4 | Terminated | Drug: simvastatin, Comparator: Placebo | Systemic Lupus Erythematosus | 4 | 2008-02-01actual | — | 2024-05-23 |
| To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)NCT00276458results2009-07-08Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Comparator: atorvastatin, Comparator: Placebo, Comparator: ezetimibe, Comparator: Placebo. | Hypercholesterolemia | 196 | Jan 2008actual | — | 2024-05-13 |
| The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)NCT00359216results2009-08-03Apnea-Hypopnea IndexRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Mometasone furoate nasal spray, Placebo | Perennial Allergic Rhinitis, Obstructive Sleep Apnea, Sleep Disorder | 30 | Jan 2008actual | — | 2024-05-23 |
| Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)NCT00511355results2011-08-30Serum Concentration of Prothrombin Fragments 1 + 2Randomized · Open-label · Prevention | Phase 3 | Completed | Drug: NOMAC-E2, Levonorgestrel and Ethinyl Estradiol | Contraception | 121 | Jan 2008actual | — | 2022-02-09 |
| Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)NCT00511433results2011-08-29Effect on Ovarian Function as Determined by the Number of Participants With an Occurrence of OvulationRandomized · Open-label · Prevention | Phase 3 | Completed | Drug: NOMAC-E2, DRSP-EE | Contraception | 48 | Jan 2008actual | — | 2022-02-09 |
| Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)NCT00381485results2011-03-07Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI) | Asthma | 834 | 2008-01-01actual | — | 2024-05-20 |
| Singulair(R) In Asthma And Allergic Rhinitis (0476-383)NCT00545844results2009-08-19Asthma ControlNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: montelukast sodium | Asthma | 313 | 2008-01-01actual | — | 2024-05-23 |
| A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)NCT00546052results2009-06-23Change in Hemoglobin A1c Between 52 Weeks and BaselineNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: losartan potassium (+) hydrochlorothiazide | Hypertension, Metabolic Disorder | 1,738 | 2008-01-01actual | — | 2024-05-16 |
| 40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)NCT00145509results2010-04-16Number of Participants Who Experienced an Adverse EventNon-randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine, Placebo | Bipolar Disorder | 77 | Dec 2007actual | — | 2022-02-08 |
| 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)NCT00265343results2010-02-23Long-term Change in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) ScaleNon-randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: asenapine, olanzapine | Schizophrenia | 306 | Dec 2007actual | — | 2022-02-09 |
| Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)NCT00704769results2009-08-11observationalAdverse Events | — | Completed | Drug: Desloratadine (assigned by investigator as part of normal practice) | Rhinitis | 591 | Dec 2007actual | — | 2022-02-09 |
| Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)NCT00705081results2009-08-03observationalNumber of Participants Reporting Adverse Events | — | Completed | Drug: ezetimibe, statin | Hypercholesterolemia | 453 | Dec 2007actual | — | 2022-02-09 |
| Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic UrticariaNCT00724698results2009-07-17observationalAdverse Events | — | Completed | Drug: Desloratadine | Rhinitis, Urticaria | 3,011 | Dec 2007actual | — | 2022-02-09 |
| Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®NCT01304511observationalNumber of retrieved oocytes by COH based on Per stage approach | — | Completed | Drug: Orgalutran | Fertilization in Vitro | 711 | Dec 2007actual | — | 2024-04-03 |
| Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)NCT00379288results2010-08-12The Number of All Randomized Subjects Reporting Adverse Events (AEs).Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: mometasone furoate combination MDI 200/10 mcg BID, mometasone furoate combination MDI 400/10 mcg BID, Fluticasone/Salmeterol 250/50 mcg BID, Fluticasone/Salmeterol 500/50 mcg BID | Asthma | 404 | Nov 2007actual | — | 2024-05-20 |
| Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)NCT00406783results2009-03-06The Change From Baseline in the 12-hour AM/PM-PRIOR (Reflective) Total 5 Symptom Score (T5SS) From Subject Daily Diaries Averaged Over Treatment Days 1 to 15Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: 5-mg Desloratadine, Placebo | Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial | 547 | Nov 2007actual | — | 2024-05-20 |
| A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)NCT00696800results2014-08-21Percentage of Participants With an Ongoing Pregnancy (Ongoing Pregnancy Rate)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Corifollitropin alfa, Placebo Corifollitropin alfa, Placebo RecFSH / follitropin beta, Ganirelix · Biological: RecFSH / Follitropin beta (Days 1 to 7), RecFSH / Follitropin beta (Days 8 to hCG), hCG, Progesterone | In Vitro Fertilization | 1,509 | 2007-11-19actual | — | 2024-06-20 |
| Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)NCT00702520results2014-06-20observationalNumber of Expectant Mothers Experiencing Adverse Events (AEs) | — | Completed | Drug: Corifollitropin alpha (MK-8962, Org 36286) 100 ug, Corifollitropin alpha (MK-8962, Org 36286) 150 ug, Triptorelin · Biological: Recombinant follicle stimulating hormone (recFSH), Human chorionic gonadotprophin (hCG). | Pregnancy, Neonates | 15 | 2007-11-07actual | — | 2024-09-05 |
| Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)NCT00166504results2008-11-05LDL-C Lowering EfficacyRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: ezetimibe (+) simvastatin, atorvastatin | Hypercholesterolemia | 203 | Oct 2007actual | — | 2024-05-22 |
| Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)NCT00408863To show non-inferiority in breast cancer recurrence of tibolone 2.5 mg versus placebo in women with climacteric symptoms who have been surgically treated for primary breast cancer within the last 5 yearsRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: tibolone, placebo | Breast Cancer, Climacteric Symptoms | 3,148 | Oct 2007actual | — | 2022-02-04 |
| Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)NCT00442559results2008-11-18Change From Baseline for Daytime Asthma Symptom ScoreRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: montelukast sodium, inhaled corticosteroid | Asthma, Allergic Rhinitis | 191 | Oct 2007actual | — | 2024-05-13 |
| A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)NCT00447603results2014-03-05Change From Baseline in Sitting Trough Systolic Blood Pressure (SiSBP) at Week 4 of Double-blind Treatment PeriodRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Achieving site readiness and enrolling the trial within a reasonable time | Drug: hydrochlorothiazide (+) losartan potassium, losartan potassium, Placebo for Losartan, Placebo for Losartan/HCTZ | Hypertension | 40 | 2007-10-22actual | — | 2024-06-18 |
| Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)NCT00156065results2010-04-07Loss of Effect Over TimeRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Haloperidol, Asenapine, Asenapine | Schizophrenia | 187 | Sep 2007actual | — | 2022-02-08 |
| Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)NCT00157924LDL-C lowering efficacyRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: simvastatin (+) ezetimibe, atorvastatin | Hypercholesterolemia | 190 | Sep 2007actual | — | 2024-06-07 |
| The Singulair® add-on Study Effectiveness of Adding Montelukast to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma (0476-384)NCT00755794To describe the percentage of patients with asthma who will be controlled after 8 weeks of treatment with montelukast used in combination with inhaled corticosteroidsNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: montelukast sodium | Asthma | 800 | Sep 2007actual | — | 2024-06-07 |
| A Trial to Assess the Pharmacokinetic Profile (e.g., Uptake, Distribution and Excretion of a Substance in the Body) of Nomegestrol Acetate (NOMAC), Estradiol (E2) and Estrone (E1) After Multiple and Single Dose Administration of the Combined Oral Contraception NOMAC-E2 (COMPLETED)(P05822)NCT00711607Plasma concentrations of NOMAC and serum concentrations of E2 and E1 measured at several time points before, during and after multiple dose and after single dose administration to determine pharmacokineticsRandomized · Double-masked · Other | Phase 1 | Completed | Drug: nomegestrol acetate and estradiol | Healthy | 25 | 2007-09-01actual | — | 2022-02-03 |
| Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)NCT00442338results2009-07-14Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After AdministrationRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: montelukast sodium, montelukast sodium, aminophylline hydrate | Asthma | 91 | Aug 2007actual | — | 2022-02-02 |
| Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)NCT00289874results2010-10-01Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: Placebo | Asthma | 421 | Jul 2007actual | — | 2022-02-02 |
| Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)NCT00468312results2010-06-22Change From Baseline in Average AM Instantaneous (NOW) Total Nasal Symptom Score (TNSS) Averaged Over Days 2 to 15Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate nasal spray, Placebo | Seasonal Allergic Rhinitis | 429 | Jul 2007actual | — | 2022-02-09 |
| This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)NCT00491504results2010-04-05Changes in the Total Nasal Symptom Severity Score (TNSS) at 6 Hours After Dosage Administration on Day 1Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Mometasone Furoate Nasal Spray · Other: Placebo | Seasonal Allergic Rhinitis | 310 | Jul 2007actual | — | 2022-02-09 |
| Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)NCT00652327results2010-06-10Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of TreatmentRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin), Double Statin (simvastatin, atorvastatin, or pravastatin) | Hypercholesterolemia | 83 | Jul 2007actual | — | 2022-02-09 |
| Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)NCT00652431Evaluate the potential for a PK interaction between NIASPAN and components of VYTORIN, using Tmax, Cmax, and AUC.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Vytorin + Niaspan, Vytorin, Niaspan | Hypercholesterolemia, Hyperlipidemia | 18 | Jul 2007actual | — | 2022-02-16 |
| Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)NCT00726856observationalEvaluation of the change in LDL-C levels after treatment | — | Completed | Drug: Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate | Dyslipidemia | 1,200 | Jul 2007actual | — | 2022-02-16 |
| To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)NCT00702845results2015-04-27Number of Cumulus-oocyte-complexes Retrieved, Per AttemptRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: corifollitropin alfa (Org 36286), recFSH (follitropin beta), gonadatropin releasing hormone (GnRH) antagonist (ganirelix), human chorion gonadatropin (hCG), placebo-recFSH (follitropin alfa), placebo-corifollitropin alfa · Biological: progesterone, open-label recFSH | Infertility | 397 | 2007-07-07actual | — | 2024-06-18 |
| Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)NCT00129402results2010-02-11Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe with simvastatin, simvastatin | Hypercholesterolemia | 248 | Jun 2007actual | — | 2022-02-08 |
| Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)NCT00156091To assess long-term safety including overall symptoms (AEs; SAEs); Vital signs; ISST; EPS; and maintenance of effect; for asenapine with haloperidol control.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Olanzapine, Asenapine · Other: Placebo | Schizophrenia | 260 | Jun 2007actual | — | 2022-02-16 |
| Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)NCT00395603Percentage reduction in ldl-c at end-point after 6 weeks.Randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: This study was terminated early due to poor recruitment. | Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks, Comparator: atorvastatin / Duration of Treatment: 6 Weeks | Cardiovascular Diseases, Diabetes Mellitus | 550 | Jun 2007actual | — | 2024-08-15 |
| Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)NCT00453063results2010-05-17Change From Baseline in the Average AM Instantaneous (NOW) Total Nasal Symptom Score (TNSS) Averaged Over Days 2 to 15Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: mometasone furoate, Placebo | Seasonal Allergic Rhinitis | 426 | Jun 2007actual | — | 2022-02-09 |
| Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)NCT00212836Changes from baseline at 6-months in Negative symptoms of schizophrenia measured by the Negative Symptoms Assessment (NSA) scaleRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: asenapine, olanzapine | Schizophrenia | 481 | 2007-06-15actual | — | 2024-08-15 |
| A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)NCT00132717Evaluate the effectiveness of MK0653A compared to doubling the statin dose as shown by the low-density lipoprotein cholesterol (LDL-C) values achieved after 12 weeks of treatmentRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: MK0653A (ezetimibe [+] simvastatin), Comparator: atorvastatin, Comparator: fluvastatin, Comparator: lovastatin, Comparator: pravastatin, Comparator: rosuvastatin, Comparator: simvastatin | Hypercholesterolemia | 450 | 2007-06-01actual | — | 2024-08-15 |
| Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)NCT00652847The primary measure of efficacy will be the percent change in plasma LDL-cholesterol between baseline and the final study assessment after six weeks of treatment.Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: ezetimibe, statins | Hypercholesterolemia | 1,140 | May 2007actual | — | 2024-08-15 |
| 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)NCT00159783results2010-07-16Participants Who Experienced Adverse Event(s)Non-randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: asenapine, Olanzapine | Bipolar Disorder | 218 | Apr 2007actual | — | 2022-02-09 |
| Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)NCT00442351results2010-04-16Change From Baseline to Final/Terminal Visit in Forced Expiratory Value in 1 Second (FEV1) in Morning Office Measurements.Randomized · Double-masked · Treatment | Phase 4 | Terminatedsponsor's stated reason: Slow Enrollment | Drug: Asmanex twisthaler · Other: Placebo for Asmanex twisthaler | Asthma | 26 | Apr 2007actual | — | 2022-02-09 |
| Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)NCT00398541Neuropsychological tests and blood pressure after treatment of 12 weeksRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: losartan potassium (+) hydrochlorothiazide | Hypertension | 41 | 2007-04-10actual | — | 2024-08-15 |
| Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)NCT00092989Improvement in forced expiratory volume in 1 second [FEV1] within the first 60 minutes after administrationRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, placebo | Asthma | 650 | Mar 2007actual | — | 2024-08-15 |
| A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788)NCT00702351serum inhibin-B levels; follicle number and follicle size distributionNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Org 36286 (corifollitropin alfa) | In Vitro Fertilization | 50 | 2007-03-26actual | — | 2022-02-02 |
| Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)NCT00423995Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Loratadine/montelukast combination | Seasonal Allergic Rhinitis | 379 | 2007-03-01actual | — | 2024-08-15 |
| 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)NCT00145470results2019-09-16Least Squares Mean Change From Baseline in Young-Mania Rating Scale (Y-MRS) Score at Day 21Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine, Placebo | Bipolar Disorder | 326 | 2007-02-28actual | — | 2024-05-21 |
| EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)NCT00166530Switching to a combination tablet of ezetimibe 10 mg plus simvastatin 20 mg is superior to doubling the statin dose as demonstrated by the percentage of patients reaching goal after 12 weeks of treatment.Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: ezetimibe (+) simvastatin, simvastatin, atorvastatin | Atherosclerosis | 367 | Feb 2007actual | — | 2024-08-15 |
| Obese Hypertension Study (0954-315)NCT00289887results2010-05-27Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Comparator: losartan +/- HCTZ, Comparator: Placebo | Hypertension | 261 | Feb 2007actual | — | 2022-02-09 |
| Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)NCT00423488results2010-03-09Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of TreatmentRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Ezetimibe 10 mg, Simvastatin 20 mg, Ezetimibe Placebo, Simvastatin 20 mg, Simvastatin Placebo | Hypercholesterolemia, Diabetes Mellitus, Type 2, Coronary Disease | 93 | 2007-02-16actual | — | 2022-02-09 |
| Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)NCT00403793% of men who had a sperm concentration of 1 million/ml or less at week 16.Randomized · Double-masked · Prevention | Phase 2 | Completed | Drug: etonogestrel with testosterone undecanoate, Placebo | Contraception | 350 | Dec 2006actual | — | 2022-02-04 |
| The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)NCT00943852results2010-07-15Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mgRandomized · Double-masked · Diagnostic | Phase 1 | Completed | Drug: losartan potassium, Comparator: isosorbide mononitrate (ISMN), Comparator: losartan + ISMN, Comparator: losartan + ISMN, Comparator: Placebo | Hypertension | 13 | Dec 2006actual | — | 2022-02-09 |
| Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)NCT00413972results2010-05-25Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of TreatmentRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe with simvastatin, Ezetimibe with Simvastatin, Ezetimibe with Simvastatin, Placebo | Hypercholesterolemia | 392 | Nov 2006actual | — | 2022-02-09 |
| Montelukast Back to School Asthma Study (0476-340)NCT00461032results2010-02-04Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic ParticipantsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast, Comparator: Placebo | Asthma | 1,162 | Nov 2006actual | — | 2022-02-02 |
| Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)NCT00202904To compare the efficacy of ezetimibe 10 mg added daily to ongoing treatment with atorvastatin 10 mg versus placebo added daily to ongoing treatment with atorvastatin 10 mg in reducing the concentration of LDL-C at endpointRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: ezetimibe, placebo | Hypercholesterolemia, Coronary Heart Disease | 81 | Oct 2006actual | — | 2022-02-16 |
| MK0476 Study in Adult Patients With Acute Asthma (0476-322)NCT00229970results2009-07-17The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: Placebo | Asthma | 225 | Oct 2006actual | — | 2022-02-02 |
| Study to Test a Marketed Product in the Treatment of Migraine-associated NauseaNCT00250458results2010-06-23Participants With Elimination of Nausea at 2 Hours PostdoseRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Comparator: Rizatriptan, Comparator: Placebo | Migraine | 346 | Oct 2006actual | — | 2022-02-03 |
| Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)NCT00319449results2011-05-10Low Density Lipoprotein-cholesterol (LDL-C) at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mgRandomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Ezetimibe, Placebo, Atorvastatin 10 mg | Hypercholesterolemia, Coronary Arteriosclerosis | 22 | Oct 2006actual | — | 2022-02-09 |
| Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)NCT00358527results2010-03-11Mean Change of the AM-PRIOR-reflective (Participant's Status Over the Previous 12 Hours) Total Nasal Symptoms Severity Score (TNSS) Averaged Over the Last 7 Days of Treatment From the Baseline Score.Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Mometasone Furoate Nasal Spray (MFNS) · Other: Placebo | Seasonal Allergic Rhinitis | 401 | Oct 2006actual | — | 2022-02-08 |
| A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)NCT00101439results2016-06-10Total Cholesterol Concentration of Chylomicron (Sf≥400) Fractions After a Cholesterol-Rich Test MealRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe, Comparator: placebo | Hypercholesterolemia | 58 | 2006-10-24actual | — | 2024-06-18 |
| Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)NCT00212771Change in total PANSS score at endpointRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: asenapine, olanzapine | Schizophrenia, Schizoaffective Disorder | 440 | Sep 2006actual | — | 2022-02-16 |
| Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)NCT00245570results2010-05-27Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Post-dose in Patients With Exercise-Induced Bronchoconstriction (EIB)Randomized · Double-masked · Prevention | Phase 3 | Completed | Drug: Comparator: Montelukast, Comparator: Salmeterol, Comparator: Placebo (montelukast), Comparator: Placebo (salmeterol) | Asthma, Exercise-Induced | 47 | Sep 2006actual | — | 2022-02-02 |
| An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)NCT00449111Change of diastolic blood pressure after 6 weeks of treatment with cozaar plusNon-randomized · Open-label · Treatment | Phase 3 | Terminated | Drug: MK0954, losartan potassium / Duration of Treatment - 12 weeks | Hypertension | 11 | 2006-09-30actual | — | 2024-08-15 |
| Trial to Evaluate Tibolone in the Treatment of Osteoporosis (P06468)NCT00519857The primary efficacy parameter was reduction in incident new vertebral fractures assessed by spinal radiographs (anterior-posterior and lateral)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Tibolone, Placebo | Osteoporosis | 4,534 | Aug 2006actual | — | 2022-02-03 |
| Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)NCT00156104Improvement in schizophrenia (change in total PANSS score) from baseline to endpoint (LOCF/MMRM)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine, Asenapine, Haloperidol · Other: Placebo arm | Schizophrenia | 460 | 2006-08-18actual | — | 2024-08-15 |
| A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)NCT00803790results2011-05-09Part 1: Urinary Excretion of AlendronateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: alendronate sodium+vitamin D combination, Comparator: alendronate · Dietary supplement: Comparator: Vitamin D | Osteoporosis | 318 | Jul 2006actual | — | 2022-02-03 |
| Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)NCT00400218Blood pressure over 12 weeksNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks | Hypertension | 62 | 2006-07-01actual | — | 2024-08-15 |
| An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272)NCT00076973Percentage of Symptom-Free DaysRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: placebo | Bronchiolitis | 1,125 | Jun 2006actual | — | 2024-08-15 |
| Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)NCT00651014Percentage of patients reaching LDL-C goal of < 2.5 mmol/L (97 mg/dL) at endpoint.Randomized · Triple-masked · Treatment | Phase 4 | Terminatedsponsor's stated reason: slow subject recruitment and lack of medical and scientific merit due to change in new standard of therapy during that same period. | Drug: Ezetimibe, Placebo | Hypercholesterolemia, Atherosclerosis | 82 | Jun 2006actual | — | 2022-02-17 |
| 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)NCT00143182Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating ScaleNon-randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine, Olanzapine | Bipolar Disorder | 504 | 2006-06-28actual | — | 2024-08-15 |
| Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)NCT00319995Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: loratadine; montelukast | Rhinitis, Allergic, Seasonal | 1,095 | 2006-06-01actual | — | 2024-08-15 |
| A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)NCT00250445Incidence of Confirmed Thrombotic Cardiovascular Serious Adverse Experiences based on combined data from this trial and MK0663 Protocols 061 & 072 (GI Tolerability in OA Patients and GI Tolerability Study in RA Patients ), respectively.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0663, etoricoxib, Comparator: Diclofenac sodium | Rheumatoid Arthritis,Osteoarthritis | 23,498 | May 2006actual | — | 2022-02-18 |
| The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)NCT00359138results2010-11-01Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week TreatmentRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: desloratadine, levocetirizine, Desloratadine placebo tablet, Levocetirizine placebo capsule | Hypersensitivity | 36 | May 2006actual | — | 2022-02-09 |
| SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)NCT00445107Change of the asthma control questionnaire scores taken over 8 weeksNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MK0476, montelukast sodium / Duration of Treatment: 8 Weeks | Asthma | 198 | 2006-05-01actual | — | 2024-08-15 |
| 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)NCT00159744Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine, Olanzapine, Placebo | Bipolar Disorder | 488 | 2006-04-29actual | — | 2024-08-15 |
| Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)NCT00156117Change in total PANSS score at endpoint (6-week double-blind or last assessment after baseline) from baselineRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: asenapine, Placebo, olanzapine | Schizophrenia | 417 | 2006-04-28actual | — | 2024-08-15 |
| Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)NCT00552097Change in ultrasound-determined average carotid artery intima-media thickness (IMT) on a per subject basis between baseline and endpoint.Randomized · Triple-masked · Prevention | Phase 3 | Completed | Drug: ezetimibe (plus simvastatin), placebo (plus simvastatin) | Atherosclerosis, Hypercholesterolemia, Hyperlipoproteinemia Type II | 720 | 2006-04-25actual | — | 2024-08-15 |
| To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)NCT00398294Total cholesterol, ldl-c, hdl-c, and triglycerides after 12 weeksNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: MK0733, simvastatin / Duration of Treatment: 12 Weeks | Hypercholesterolemia | 30 | 2006-04-04actual | — | 2024-08-15 |
| 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)NCT00159796Change from Baseline to Day 21 on the Young Mania Rating Scale (YMRS) Total ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Asenapine, Olanzapine, Placebo | Bipolar Disorder | 489 | 2006-03-28actual | — | 2024-08-15 |
| Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)NCT00212784Change in total PANSS score at endpoint (52-week double-blind or last assessment after baseline) from baselineRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: asenapine, olanzapine | Schizophrenia, Schizoaffective Disorder | 1,225 | 2006-03-15actual | — | 2024-08-15 |
| The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)NCT00276016results2010-07-29The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Phenylephrine Compared With PlaceboRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: phenylephrine, pseudoephedrine, placebo | Rhinitis, Allergic, Seasonal | 39 | Feb 2006actual | — | 2022-02-09 |
| Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)NCT00111709Percentage of patients with 2 hour pain relief: 4-point headache severity scale as recorded in patient diaryRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1 day, Comparator: placebo / Duration of Treatment - 1 day | Migraine | 393 | 2006-02-24actual | — | 2024-08-14 |
| Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)NCT00111722Percentage of patients with 2 hour pain relief: 4-point headache severity scale as recorded in patient diaryRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1day, Comparator: placebo / Duration of Treatment - 1 day | Migraine | 393 | 2006-02-15actual | — | 2024-08-14 |
| Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)NCT00157963Antihypertensive efficacy of 12 weeks of treatment with hydrochlorothiazide (+) losartan potassium/amlodipineRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks | Essential Hypertension | 174 | 2006-02-08actual | — | 2024-08-15 |
| TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)NCT00328523Percent of patients attaining the ldl cholesterol target goal based on the lipids result at the end of the study (3 months).Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MK-0653, ezetimibe, Duration of Treatment: 3 months | Hypercholesterolaemia, Hyperlipidaemia | 1,496 | Jan 2006actual | — | 2024-08-15 |
| Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)NCT00380627Perception of menstrual pain, through the analog verbal scale during three days.Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days | Pain | 337 | 2006-01-31actual | — | 2024-08-15 |
| To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)NCT00398151Ltd4 in urine and eosinophil from peripheral blood over 3 months of therapyNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MK0476, montelukast sodium / Duration of Treatment: 12 Weeks | Asthma | 58 | 2006-01-18actual | — | 2024-08-15 |
| Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)NCT00151424Change in total Positive and Negative Syndrome Scale (PANSS) score at endpoint (6-week double-blind or last assessment after baseline) from baselineRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: asenapine, Placebo, Olanzapine | Schizophrenia | 277 | 2006-01-06actual | — | 2024-08-15 |
| A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)NCT00732368Change from Baseline in 4 nasal symptom score.Open-label · Treatment | Phase 3 | Completed | Drug: Mometasone furoate | Perennial Allergic Rhinitis | 98 | 2006-01-01actual | — | 2024-08-15 |
| Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)NCT00092742Discontinuations due to clinical and laboratory gastrointestinal adverse experiencesRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0663, etoricoxib, Comparator: Diclofenac sodium | Rheumatoid Arthritis | 4,086 | Dec 2005actual | — | 2022-02-16 |
| A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)NCT00110435Percent reduction in LDL-C from baseline after 6 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653A, ezetimibe (+) simvastatin, Duration of Treatment: 4 wk placebo run in then 6 wk active, Comparator: atorvastatin | Type 2 Diabetes Mellitus, Hypercholesterolemia | 1,229 | Dec 2005actual | — | 2024-08-15 |
| Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)NCT00651560Evaluate the hypolipidemic effect of Vytorin after 4 weeks treatment in adult patients with mix dislipidemia to reduce the cardiovascular risk and achieve the ATP-III goals.Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: ezetimibe (+) simvastatin | Hyperlipidemia | 167 | 2005-12-23actual | — | 2024-08-15 |
| Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)NCT00395473Percent (%) reduction in plasma low-density lipoprotein cholesterol (ldl-c) concentration after 6 weeks of treatmentNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe / Duration of Treatment: 6 Weeks | Hypercholesterolemia | 141 | Nov 2005actual | — | 2024-05-10 |
| Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)NCT00457275ApprovalRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe / Duration of Treatment: 4 Weeks | Hypercholesterolemia | 440 | Nov 2005actual | — | 2024-08-15 |
| Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)NCT00724789observationalTo collect data on the incidence of congenital malformations in infants of women with an ongoing pregnancy after controlled ovarian hyperstimulation. | — | Completed | Drug: ganirelix, GnRH agonist | Pregnancy, Neonates | 2,066 | Nov 2005actual | — | 2022-02-03 |
| A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED)NCT00725413PregnancyOpen-label · Treatment | Phase 4 | Completed | Drug: etonogestrel implant (Implanon) | Contraception | 210 | Nov 2005actual | — | 2022-02-04 |
| A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)NCT00783224results2010-07-12Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 WeeksRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: Placebo for MF, Placebo for FP, Mometasone, Fluticasone | Perennial Allergic Rhinitis | 351 | Nov 2005actual | — | 2022-02-09 |
| Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)NCT00413764Compare the effect of tibolone (2.5 mg) to transdermal E2/NETA (50/140 mcg) on the vaginal bleeding and spotting rate in healthy postmenopausal women with sexual dysfunction.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: tibolone, estradiol-norethisterone | Sexual Dysfunction | 358 | 2005-11-15actual | — | 2022-02-04 |
| Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297)NCT00394160To evaluate the safety and tolerability of montelukast oral granules in children aged 1 to 3 months.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: MK0476, Montelukast Sodium /Duration of Treatment : 14 Days | Bronchiolitis | 12 | Oct 2005actual | — | 2024-08-15 |
| Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)NCT00779116results2010-07-05Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.Randomized · Open-label · Other | Phase 4 | Completed | Drug: Desloratadine, Zyrtec® (cetirizine) | Allergies | 217 | Oct 2005actual | — | 2022-02-09 |
| Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)NCT00780403results2010-07-30Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.Randomized · Open-label · Other | Phase 4 | Completed | Drug: Desloratadine, Zyrtec® (cetirizine) | Allergies | 220 | Oct 2005actual | — | 2022-02-09 |
| An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)NCT00878462The response to the question: "How likely would you be to take this medication for at least 1 year if your doctor continued to prescribe it to you and it worked well?""Randomized · Open-label · Other | Phase 2 | Completed | Drug: Asenapine WHITE raspberry flavor (Treatment A), Asenapine RED raspberry flavor (Treatment B), Asenapine WHITE UNFLAVORED (Treatment C) | Psychosis | 174 | 2005-10-15actual | — | 2024-08-15 |
| An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)NCT00092898Sitosterol concentrations after 26 weeks.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe, Comparator: placebo | Lipid Metabolism, Inborn Errors, Heart Disease | 30 | Sep 2005actual | — | 2024-08-15 |
| A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)NCT00093899Plasma LDL-C.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ezetimibe (+) simvastatin | Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia | 611 | Sep 2005actual | — | 2024-08-15 |
| Eze/Simva Switch Study in Diabetics (0653A-807)NCT00541697Determine the additional LDL-C lowering achieved by switching to MK0653A as compared to Atorvastatin after 6 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks, Comparator: atorvastatin / Duration of Treatment: 6 Weeks | Diabetes Mellitus, Type 2 | 648 | 2005-09-28actual | — | 2024-08-15 |
| Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)NCT00731185Time to relapse in polyp score after surgeryRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Mometasone Furoate Nasal Spray, Placebo | Nasal Polyps | 162 | 2005-09-01actual | — | 2024-08-15 |
| 4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)NCT00641771To compare change in fractional calcium absorption following administration of MK0217A relative to matching placebo, in postmenopausal women with osteoporosisRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: alendronate sodium (+) cholecalciferol, Comparator: Placebo (unspecified) | Osteoporosis | 56 | Aug 2005actual | — | 2022-02-02 |
| Study of Investigational Drug in Osteoporosis (MK-0217-908)NCT00092053Change in serum levels of CTX-I (log-transformed fraction) from Week 9 to Week 12Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Placebo, ibandronate | Postmenopausal Osteoporosis | 203 | Jul 2005actual | — | 2022-02-02 |
| Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)NCT00380705Quality of life measuresNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks | Asthma, Rhinitis Allergic | 91 | 2005-07-29actual | — | 2024-08-15 |
| Tibolone Endometrium Study (Study 32972)(P06470)NCT00745108Endometrial biopsy and histological examinationRandomized · Quadruple-masked · Other | Phase 3 | Completed | Drug: tibolone, Tibolone 2.5 mg, CE/MPA | Postmenopausal Women | 32 | 2005-07-21actual | — | 2022-02-03 |
| A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)NCT00127179Change from baseline in the International Prostate Symptom ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0906, finasteride / Duration of Treatment: 48 weeks, Comparator: placebo / Duration of Treatment: 48 weeks | Benign Prostatic Hyperplasia | 600 | 2005-07-01actual | — | 2024-08-15 |
| A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)NCT00157937FEV1Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: MK0476; montelukast sodium/Duration of Treatment: 16 weeks, Comparator: theophylline ER/Duration of Treatment: 16 weeks | Asthma, Allergic Rhinitis | 31 | Jun 2005actual | — | 2024-08-15 |
| Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)NCT00816972Change from baseline in mean daily AM/PM Prior post-nasal drip scores averaged over the entire treatment periodRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Desloratadine 2.5 mg, Oxybutynin 2.5 mg, Placebo for Desloratadine 2.5 mg, Placebo for Oxybutynin 2.5 mg | Post-nasal Drip, Seasonal Allergic Rhinitis, Rhinorrhea | 540 | Jun 2005actual | — | 2022-02-16 |
| A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)NCT00140972WOMAC pain subscaleRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: MK0663; etoricoxib / Duration of Treatment:4 Weeks, Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks | Osteoarthritis | 160 | 2005-06-27actual | — | 2024-08-15 |
| MK0954A-264 Filter Study (0954A-264)(COMPLETED)NCT00307060Losartan-HCTZ 100-12.5 mg combination will be more effective in lower mean through sitting diastolic blood pressure (SiDBP) than losartan 100 mg monotherapy after 6 weeks of treatment.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks, losartan / Duration of Treatment: 6 weeks | Mild to Severe Hypertension | 274 | 2005-06-01actual | — | 2024-08-15 |
| Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)NCT00651378Percent change in LDL-C level from baseline to the study endpoint.Randomized · Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Slow enrollment \[HIGH SCREEN FAILURE RATE\] | Drug: Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin | Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease | 87 | 2005-06-01actual | — | 2024-08-15 |
| Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)NCT00092833Incidence of clinical and laboratory adverse experiences in in patients with homozygous FH or homozygous sitosterolemia taking ezetimibe 10 mg/dayNon-randomized · Open-label · Treatment | Phase 3 | Terminated | Drug: Comparator: ezetimibe | Hypercholesterolemia, Familial, Lipid Metabolism, Inborn Errors | 49 | May 2005actual | — | 2024-08-15 |
| Analgesic Treatment Mediated by Arcoxia (0663-093)NCT00380523Evaluate pain using the verbal analog scale (evaluate pain before starting treatment and then evaluate pain every day after had taken arcoxia up to three days)Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days | Pain | 237 | May 2005actual | — | 2022-02-16 |
| A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)NCT00311844Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: desloratadine | Conjunctivitis, Allergic | 41 | 2005-05-28actual | — | 2024-08-15 |
| A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)NCT00751218Compare the efficacy of the study treatments with respect to the change from Baseline in the average AM/PM 12-hour reflective pruritus severity score (diary recordings) after the first 7 days of treatment.Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: desloratadine, placebo, cetirizine | Urticaria | 174 | 2005-05-24actual | — | 2024-08-15 |
| A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)NCT00142558Patient assessment of pain (0- to 4- Likert scale)Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: MK0663; etoricoxib / Duration of Treatment: 5 Days, Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days | Acute Gout | 180 | 2005-05-01actual | — | 2024-08-15 |
| A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)NCT00751166Compare the efficacy of the study treatments with respect to the change from Baseline in the average AM/PM 12-hour reflective pruritus severity score (diary recordings)Randomized · Triple-masked · Treatment | Phase 4 | Terminatedsponsor's stated reason: Study could not be re-supplied with study medication in a timely manner. | Drug: Desloratadine, Cetirizine, placebo | Urticaria | 149 | 2005-05-01actual | — | 2024-08-15 |
| An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)NCT00127647Composite Nasal Symptom ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: pranlukast | Rhinitis, Allergic, Seasonal | 1,375 | Apr 2005actual | — | 2024-08-15 |
| A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)NCT00725374The primary objective of this trial was to compare changes in the expression of the proliferation marker Ki-67 in malignant breast tissue after treatment with tibolone or placebo.Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: tibolone, placebo | Breast Cancer | 102 | 2005-04-15actual | — | 2024-08-15 |
| Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)NCT00095004Percentage of patients who are pain free at 2 hours postdoseRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day, Comparator: placebo / Duration of Treatment: 1 day | Migraine | 167 | 2005-04-01actual | — | 2024-08-14 |
| Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)NCT00779740Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2.Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: mometasone furoate, mometasone furoate | Rhinitis, Allergic, Perennial | 102 | 2005-04-01actual | — | 2024-08-15 |
| Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)NCT00090181Lower back pain intensityRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: MK0663, etoricoxib / Duration of Treatment: 4 weeks, Comparator: diclofenac / Duration of Treatment: 4 weeks | Chronic Low Back Pain | 401 | Mar 2005actual | — | 2022-02-15 |
| Trial to Compare the Effects of Tibolone (Livial®) and Continuous Combined Low-Dose Estradiol/Noresterone (Activelle®)NCT00431093For the bleeding evaluation, subject will be given a diary card to record the days on which no bleeding, vaginal spotting or bleeding occursRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: tibolone, low-dose estradiol/noresterone | Menopause | 570 | Mar 2005actual | — | 2022-02-03 |
| Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)NCT00651963Lipid profileNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: ezetimibe | Lipid Metabolism Disorder | 80 | Mar 2005actual | — | 2024-08-15 |
| Pregnancy & Neonatal Follow-up of Ongoing Pregnancies Established During Clinical Trial 38826 (Study 38827)(P06056)(COMPLETED)NCT00702988observationalPregnancy status at 20 weeks of gestation | — | Completed | Drug: Org 36286, recFSH | Pregnancy, Neonates | 44 | 2005-02-28actual | — | 2022-02-03 |
| MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)NCT00771160Any clinical or laboratory adverse experienceRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: montelukast sodium | Rhinitis, Allergic | 120 | Feb 2005actual | — | 2024-08-15 |
| An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)NCT00795522Change from Baseline in the Short Form 12 (SF-12) Health Survey Questionnaire, mental, physical and total scores on treatment days 7, 14, 21, and 28.Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Desloratadine | Urticaria | 51 | Feb 2005actual | — | 2022-02-17 |
| Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)NCT00431431Measure BMD to evaluate the effects of treatment on bone mineral density of the lumbar vertebrae L1-L4Randomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: tibolone, raloxifen | Osteopenia | 324 | 2005-02-15actual | — | 2024-08-15 |
| Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)NCT00652717LDL levelsRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Ezetimibe, simvastatin | Cardiovascular Disorder | 280 | 2005-02-15actual | — | 2024-08-15 |
| A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)NCT00092768Osteoarthritis of the knee & hip as assessed by WOMAC VA 3.0 pain and physical function subscales, Patient/Investigator assessments of disease and response to therapy over 12 weeks of treatment.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0663, etoricoxib, Comparator: celecoxib | Osteoarthritis | 500 | 2005-02-01actual | — | 2024-08-15 |
| A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)NCT00092781Osteoarthritis of the knee & hip as assessed by WOMAC VA 3.0 pain and physical function subscales, Patient/Investigator assessments of disease and response to therapy over 12 weeks of treatment.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0663, etoricoxib, Comparator: celecoxib | Osteoarthritis | 500 | 2005-02-01actual | — | 2024-08-15 |
| Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)NCT00650819Percent change from baseline in LDL-C concentration.Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Ezetimibe + Simvastatin, Simvastatin, Ezetimibe | Hypercholesterolemia | 240 | 2005-02-01actual | — | 2024-08-15 |
| Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)NCT00092963Percentage of patients who are pain free at 2 hours postdose.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day, Comparator: placebo / Duration of Treatment: 1 day | Migraine | 529 | 2005-01-14actual | — | 2024-08-14 |
| ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)NCT00140907Incidence of chronic allograft nephropathyRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: losartan potassium, Comparator: Placebo | High Blood Pressure | 367 | 2005-01-01actual | — | 2024-08-15 |
| Elocon vs Fluticasone in Localized Psoriasis (P03197)NCT00763529Reduction in mean symptom scores for erythema, induration, pruritus, and scaling on Day 4.Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Mometasone, Fluticasone | Psoriasis | 245 | 2005-01-01actual | — | 2024-08-15 |
| Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04208)NCT00783458Overall product preference based on subjects' answer to the question "which product do you prefer overall"Randomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Mometasone Furoate Nasal Spray, fluticasone nasal spray | Allergic Rhinitis | 100 | 2005-01-01actual | — | 2024-08-15 |
| Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04207)NCT00817050Overall product preference based on subjects' answer to the question "which product do you prefer overall"Randomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Mometasone Furoate Nasal Spray, fluticasone nasal spray | Allergic Rhinitis | 100 | 2005-01-01actual | — | 2024-08-15 |
| Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)NCT00090298LDL-C lowering efficacy after 6 weeks.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653A, ezetimibe (+) simvastatin, Comparator: Rosuvastatin | Hypercholesterolemia | 2,815 | Dec 2004actual | — | 2024-08-15 |
| Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)NCT00650689Change from baseline to endpoint in LDL-C.Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Ezetimibe + Atorvastatin, Atorvastatin | Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease | 122 | Dec 2004actual | — | 2022-02-17 |
| Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)NCT00651404Percent change from baseline to end of treatment in LDL-C.Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Ezetimibe, Placebo | Hypercholesterolemia, Atherosclerosis | 137 | Dec 2004actual | — | 2022-02-17 |
| Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)NCT00092573TolerabilityTreatment | Phase 3 | Completed | Drug: MK0653, ezetimibe, Comparator: fenofibrate monotherapy | Hypercholesterolemia, Hypertriglyceridemia | 576 | Nov 2004actual | — | 2024-08-15 |
| Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)NCT00794378Taste acceptability as determined from smiley-face scale of 1 (frowning child) to 5 (happy child face).Randomized · Quadruple-masked · Other | Phase 3 | Completed | Drug: Desloratadine (Clarinex), Cetirizine (Zyrtec) | Allergic Rhinitis | 202 | Nov 2004actual | — | 2022-02-16 |
| Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)NCT00794794Taste acceptability as determined from smiley-face scale of 1 (frowning child) to 5 (happy child face).Randomized · Quadruple-masked · Other | Phase 3 | Completed | Drug: Desloratadine (Clarinex), Cetirizine (Zyrtec) | Allergic Rhinitis | 204 | Nov 2004actual | — | 2022-02-16 |
| Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)NCT00779636Change in FEV1 averaged over weeks 1 to 4.Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Desloratadine, Placebo | Allergic Airway Disease | 506 | 2004-11-01actual | — | 2024-08-15 |
| Montelukast in Exercise-Induced Bronchospasm - 2004 (0476-275)NCT00090142results2010-10-29Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Post-dose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)Randomized · Double-masked · Prevention | Phase 3 | Completed | Drug: Comparator: Montelukast, Comparator: Placebo | Asthma, Exercise-Induced | 62 | Oct 2004actual | — | 2022-02-02 |
| Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)NCT00090168LDL-C loweringRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653A , ezetimibe (+) simvastatin, Comparator: atorvastatin, Duration of Treatment: 6 weeks | Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease | 435 | 2004-10-20actual | — | 2024-08-15 |
| A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)NCT00092040Mean percent change from baseline in hip trochanter bone mineral density (BMD)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0217, alendronate sodium/Duration of Intervention: 12 mo, Comparator: risedronate / Duration of Intervention: 12 mo | Osteoporosis, Postmenopausal | 936 | 2004-10-18actual | — | 2024-08-14 |
| Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)NCT00783146Compare the efficacy of the study treatments with respect to the change from Baseline in the mean AM self-rated instantaneous total symptom score (TSS) (not including nasal congestion) averaged over the 15 days of treatmentRandomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: desloratadine, fexofenadine, placebo | Seasonal Allergic Rhinitis | 728 | 2004-10-01actual | — | 2024-08-15 |
| Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)NCT00783211Compare the efficacy of the study treatments with respect to the change from Baseline in the mean AM self-rated instantaneous total symptom score (TSS) (not including nasal congestion) averaged over the 15 days of treatmentRandomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: desloratadine, fexofenadine, placebo | Seasonal Allergic Rhinitis | 722 | 2004-10-01actual | — | 2024-08-15 |
| Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)NCT00653913Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin after administration of each drug alone and in combination, using Cmax and AUC(0-24h).Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: SCH 58235, pitavastatin | Hypercholesterolemia | 18 | Sep 2004actual | — | 2022-02-16 |
| Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)NCT00650663Percent change in LDL-C from baseline to endpoint.Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Ezetimibe + Simvastatin, Simvastatin | Hypercholesterolemia, Atherosclerosis | 247 | 2004-09-01actual | — | 2024-08-15 |
| Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)NCT00651391Change from baseline to endpoint in flow-mediated vasodilation: percent change in the mean diameter between 1-minute, post-cuff release diameter and image obtained prior to cuff application.Randomized · Triple-masked · Basic science | Phase 3 | Terminatedsponsor's stated reason: Slow enrollment | Drug: Ezetimibe + Simvastatin, Simvastatin, Placebo | Hypercholesterolemia, Atherosclerosis | 28 | 2004-09-01actual | — | 2024-08-15 |
| Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)NCT00652444Percentage reduction of LDL-C after 6 weeks of treatment.Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: ezetimibe, simvastatin, Placebo (Unspecified) | Hypercholesterolemia | 120 | Aug 2004actual | — | 2022-02-18 |
| Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)NCT00756418Improvement of AM PEF over first 2 WeeksRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: montelukast, Theophylline | Asthma | 84 | 2004-08-28actual | — | 2024-08-15 |
| A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)NCT00779545Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Placebo, Mometasone furoate, Mometasone furoate, Mometasone furoate, Mometasone furoate, Mometasone furoate | Rhinitis, Allergic, Perennial | 455 | 2004-08-06actual | — | 2024-08-15 |
| Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)NCT00651274Percent change from baseline in LDL-cholesterol with ezetimibe added to simvastatin versus continued simvastatin alone.Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Ezetimibe, Placebo | Atherosclerosis, Hypercholesterolemia, Coronary Heart Disease | 144 | 2004-08-01actual | — | 2024-08-15 |
| Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)NCT00653796Percent change in LDL-C from baseline to endpoint.Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Ezetimibe + Atorvastatin, Atorvastatin | Hypercholesterolemia, Atherosclerosis | 148 | 2004-08-01actual | — | 2024-08-15 |
| Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)NCT00653835Percent change in LDL-C from baseline to endpoint.Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Ezetimibe + Simvastatin, Simvastatin | Hypercholesterolaemia, Atherosclerosis | 153 | 2004-08-01actual | — | 2024-08-15 |
| Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)NCT00092625Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe, Comparator: ezetimibe, placebo | Hypercholesterolemia, Coronary Disease | 442 | Jul 2004actual | — | 2024-08-15 |
| An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)NCT00092638Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe, Comparator: ezetimibe, placebo | Hypercholesterolemia, Coronary Disease | 450 | Jul 2004actual | — | 2024-08-15 |
| Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)NCT00092092Short-term lower-leg growth rate (LLGR)Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Montelukast chewable tablets, Budesonide inhaler, Placebo to montelukast chewable tablets, Placebo to budesonide inhaler | Asthma, Bronchial | 71 | Jun 2004actual | — | 2024-08-14 |
| Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)NCT00092599Percentage of patients reaching LDL goal of <2.60 mmol/L after 6 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe, Comparator: ezetimibe, placebo | Hypercholesterolemia, Coronary Disease | 410 | Jun 2004actual | — | 2024-08-15 |
| Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)NCT00092612Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe, Comparator: ezetimibe, placebo | Hypercholesterolemia, Coronary Disease | 372 | Jun 2004actual | — | 2024-08-15 |
| Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)NCT00140959Mean daytime ambulatory systolic blood pressureRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: MK0954, losartan potassium/Duration of Treatment: 18 weeks, Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks | Hypertension | 120 | 2004-06-30actual | — | 2024-08-15 |
| A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)NCT01044056results2010-03-31Maximum Concentration (Cmax) (Pharmacokinentic Parameter (PK)) for All Subjects in the Pharmacokinetically Evaluable (ASPE) GroupRandomized · Open-label · Basic science | Phase 4 | Completed | Drug: Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets, norelgestrominum and ethinylestradiol patch oral contraceptive patch, Nuvaring ™ (etonorgestrel/ethinylestradiol) | Contraception | 24 | Jun 2004actual | — | 2022-02-04 |
| Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)NCT00446056Improvement of morning peak expiratory flow over first 2 weeksRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: MK0476, montelukast sodium / Duration of Treatment: 4 Weeks, Comparator: ketotifen / Duration of Treatment: 4 Weeks | Asthma | 188 | 2004-06-16actual | — | 2024-08-15 |
| Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)NCT00092144To assess daytime asthma symptoms as measured by daily diaries over a 3-week treatment periodRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0476, montelukast sodium / Duration of Treatment: 4 weeks, Comparator: placebo / Duration of Treatment: 4 weeks | Asthma | 500 | 2004-06-15actual | — | 2024-08-15 |
| The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)NCT00092118results2010-07-23Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic RhinitisRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Montelukast, Comparator: Placebo | Rhinitis, Allergic, Perennial | 1,992 | May 2004actual | — | 2022-02-03 |
| Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)NCT00953680results2010-07-16Area Under the Curve (AUC(0 to Infinity)) of LosartanRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: losartan potassium (+) hydrochlorothiazide (HCTZ), losartan potassium, hydrochlorothiazide (HCTZ) | Hypertension | 77 | May 2004actual | — | 2022-02-09 |
| Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)NCT00751075Average AM/PM major-symptom score (sum of rhinorrhea, post nasal drip, nasal congestion/stuffiness, sinus headache, and facial pain/pressure/tenderness on palpation over the paranasal sinuses) over the Treatment Phase of 15 days.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: mometasone furoate nasal spray (MFNS), MFNS, Amoxicillin, Placebo | Acute Rhinosinusitis | 981 | 2004-05-06actual | — | 2024-08-15 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)NCT00092066Proportion of patients with Vitamin D insufficiency (defined as serum 25-hydroxyvitamin levels <15 ng/mL) after 15 weeks of treatment.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks | Osteoporosis, Vitamin D Deficiency | 717 | 2004-05-01actual | — | 2024-08-14 |
| The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)NCT00789152Change in Total Nasal Symptom Score (TNSS) at the end of treatment phase compared to pre-exposure baseline scoresRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: desloratadine, levocetirizine | Allergic Rhinitis | 81 | 2004-05-01actual | — | 2024-08-15 |
| A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)NCT00652301reduced intestinal cholesterol absorption with ezetimibe + simvastatin vs simvastatin alone.Randomized · Double-masked · Diagnostic | Phase 3 | Completed | Drug: ezetimibe, Comparator: Placebo (unspecified), simvastatin | Cholesterol | 40 | Apr 2004actual | — | 2024-08-15 |
| Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)NCT00988260Incidence of Luteinizing Hormone (LH) riseRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Ganirelix, Ganirelix, Ganirelix | Controlled Ovarian Stimulation | 266 | 2004-04-12actual | — | 2024-08-15 |
| A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)NCT00092014Mean percent change from baseline in hip trochanter bone mineral density (BMD) at 12 monthsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Alendronate, Risedronate 35 mg, Risendronate placebo, Alendronate placebo · Dietary supplement: Elemental Calcium, Vitamin D | Postmenopausal Osteoporosis | 1,053 | 2004-04-01actual | — | 2024-08-14 |
| Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270)NCT00834119To assess the mean change in total nasal symptom score from Baseline to the Final Visit of regular intranasal steroid use (mometasone furoate) in allergic rhinitis patients when used alone or in combination with an oral antihistamine.Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Mometasone furoate, Mometasone furoate | Rhinitis, Allergic | 72 | 2004-04-01actual | — | 2024-08-15 |
| MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)NCT00092690Plasma LDL-C averaged across all doses after 6 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653A, ezetimibe (+) simvastatin, Comparator: atorvastatin | Hypercholesterolemia | 1,902 | Mar 2004actual | — | 2024-05-10 |
| MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)NCT00446186The change from baseline in the composite nasal symptoms score (average over the 2-week treatment period) in seasonal allergic rhinitisRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: MK0476, montelukast sodium / Duration of Treatment: 2 Weeks, Comparator: placebo / Duration of Treatment: 2 Weeks | Rhinitis Allergic | 945 | Mar 2004actual | — | 2024-08-15 |
| Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)NCT00251576Z-Phase: combined frequency of the following clinical endpoint events: cardiovascular death, MI, readmission for ACS.Randomized · Double-masked · Prevention | Phase 3 | Completed | Drug: A-Phase: tirofiban; Z-Phase simvastatin, Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years, Comparator: A-Phase: low molecular weight heparin, unfractionated heparin, Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours, Duration of Treatment: Z-Phase, 2 years. | Acute Coronary Syndrome | 4,497 | 2004-03-23actual | — | 2024-08-15 |
| A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)NCT00092027To evaluate the upper gastrointestinal (UGI) safety and tolerability of 6 months of treatment with once weekly alendronate 70 mg in an oral buffered solution in comparison to placebo in postmenopausal women with osteoporosisRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0217, alendronate sodium/Duration of Treatment: 6 months, Comparator: placebo / Duration of Treatment: 6 months | Postmenopausal Osteoporosis | 454 | 2004-03-15actual | — | 2024-08-14 |
| A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)NCT00598208Number of cumulus-oocyte-complexes retrievedRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: corifollitropin alfa, Follitropin beta injection | Fertilization | 325 | 2004-03-15actual | — | 2024-08-15 |
| Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)NCT00783237Total Nasal Symptom Score (TNSS)Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Mometasone, Placebo | Allergic Rhinitis | 340 | 2004-02-21actual | — | 2024-08-15 |
| A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)NCT00783354Changes from Visit 2 to Visit 4 of Vq-derm questionnaire score and DLQI quality of life score.Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: desloratadine, desloratadine | Urticaria, Chronic Idiopathic Urticaria | 129 | 2004-02-01actual | — | 2024-08-15 |
| MD Ezetimibe Cyclosporine Interaction (0653-057)NCT00653276To evaluate the safety and tolerability of cyclosporine coadministered with ezetimibe vs. cyclosporine administered alone.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ezetimibe, Comparator: cyclosporine | Cholesterol | 13 | Jan 2004actual | — | 2024-08-15 |
| How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)NCT00795158Change from baseline to day 28 in Dermatology Life Quality Index (DLQI) scoreOpen-label · Treatment | Phase 3 | Completed | Drug: desloratadine | Urticaria | 282 | Jan 2004actual | — | 2022-02-17 |
| Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)NCT00092560Plasma LDL-C vs. fenofibrate for 12 weeks.Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe, Comparator: fenofibrate monotherapy | Hypercholesterolemia, Hypertriglyceridemia | 587 | Dec 2003actual | — | 2024-08-15 |
| PK Study in 3- to 6- Month-Old Children (0476-268)(COMPLETED)NCT00394069To evaluate the safety and tolerability of montelukast oral granules in children aged 3 to 6 months.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: MK-0476, montelukast sodium | Bronchiolitis | 14 | Dec 2003actual | — | 2024-08-14 |
| Linear Growth Study (0476-097)(COMPLETED)NCT00395408To establish the difference in the average rate of linear growth over the 56-week double-blind treatment period between the montelukast and placebo groupsRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: MK0476, montelukast sodium / Duration of Treatment : 56 Weeks, Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks | Asthma | 360 | Dec 2003actual | — | 2024-08-14 |
| First Step With Singulair® Therapy (0476-323)NCT00545324Canadian asthma guidelines criteriaRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks, Comparator: Fluticasone / Duration of Treatment: 6 Weeks | Asthma | 399 | Dec 2003actual | — | 2024-08-15 |
| Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270)NCT00092131results2010-06-17Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Postdose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)Randomized · Double-masked · Prevention | Phase 3 | Completed | Drug: Comparator: Montelukast, Comparator: Placebo | Asthma, Exercise-Induced | 51 | Nov 2003actual | — | 2022-02-02 |
| Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)NCT00070707results2019-07-18Change From Baseline in Morning (AM) and Evening (PM) Total Asthma Symptom Severity (TASS)Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Mometasone, Placebo, Albuterol/Salbutamol | Rhinitis, Allergic, Seasonal, Asthma | 188 | 2003-11-26actual | — | 2024-09-05 |
| An Investigational Drug in Patients With Osteoarthritis (0663-073)NCT00092755WOMAC VA 3.0 pain subscale, WOMAC VA 3.0 physical function subscale, and Patient Global Assessment of Disease Status Scale. Efficacy data collected at Weeks 2, 4, 8, and 12.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0663, etoricoxib, Comparators: ibuprofen and placebo | Osteoarthritis | 548 | 2003-11-13actual | — | 2024-08-15 |
| A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED)NCT00269191Pain and physical function over 12-weeks as assessed by the WOMAC VA 3.0 pain subscale, WOMAC VA 3.0 physical function subscale, and Patient Global Assessment of Disease Status, as well as safety over 12-weeks as assessed by adverse experiences.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0663, etoricoxib / Duration of Treatment 12 Weeks, Placebo or Ibuprofen / Duration of Treatment 12 Weeks | Osteoarthritis | 528 | 2003-11-07actual | — | 2024-08-15 |
| Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)NCT00092703Discontinuations due to clinical and laboratory gastrointestinal adverse experiences during a 1 year treatment period.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0663, etoricoxib, Comparator: Diclofenac sodium | Osteoarthritis | 6,000 | 2003-11-01actual | — | 2024-08-15 |
| Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)NCT00092586Percent change in LDL-CRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe, Comparator: statins | Hypercholesterolemia | 2,904 | Oct 2003actual | — | 2024-08-15 |
| An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)NCT00092885Daily Rhinitis Symptoms score; the Daytime Nasal Symptoms score and Nighttime Symptoms scoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0476, montelukast sodium, Comparator: placebo | Rhinitis, Allergic, Seasonal, Asthma, Bronchial | 831 | Oct 2003actual | — | 2024-08-15 |
| A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)NCT00157911LDL-CRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653; ezetimibe / Duration of Treatment: 12 weeks, Comparator: simvastatin / Duration of Treatment: 12 weeks | Hypercholerolemia | 136 | Oct 2003actual | — | 2024-08-15 |
| FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)NCT00398931Total hip bone mineral density (BMD)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0217, alendronate sodium / Duration of Treatment : 5 Years, Comparator : placebo (unspecified) /Duration of Treatment : 5 Years | Osteoporosis, Postmenopausal | 1,099 | Oct 2003actual | — | 2022-02-03 |
| Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)NCT00757562Safety and ToleranceRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: desloratadine, Placebo | Chronic Idiopathic Urticaria, Atopy | 97 | 2003-10-01actual | — | 2024-08-15 |
| An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)NCT00092664Plasma LDL-C.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks | Hypercholesterolemia | 1,104 | Sep 2003actual | — | 2024-08-15 |
| Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials of Org 36286 (Study 38817)(P06054)(COMPLETED)NCT00702195observationalPregnancy status at 20 weeks of gestation; Take-home baby rate | — | Completed | Drug: Org 36286 (corifollitropin alfa), Placebo, recFSH | Pregnancy | 29 | 2003-09-15actual | — | 2024-08-15 |
| Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)NCT00750750Average AM/PM major-symptom score (sum of rhinorrhea, post nasal drip, nasal congestion/stuffiness, sinus headache, and facial pain/pressure/tenderness on palpation over the paranasal sinuses) over the Treatment Phase of 15 days.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: mometasone furoate nasal spray (MFNS), MFNS, Amoxicillin, Placebo | Acute Rhinosinusitis | 981 | 2003-09-01actual | — | 2024-08-15 |
| A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)NCT00480766Assess the effect of patients taking MK0217 once weekly along with steroids for a 12 month period by checking the percentage change of bone mineral density as compared to patients taking placeboRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0217/Duration of Treatment : 12 Months | Osteoporosis | 173 | Aug 2003actual | — | 2024-08-14 |
| Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)NCT00794599The primary efficacy measure was the preference rates calculated from subject comparative evaluation.Randomized · Open-label · Other | Phase 4 | Completed | Drug: Desloratadine 5 mg (Clarinex), Cetirizine (Zyrtec) | Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis | 118 | Aug 2003actual | — | 2022-02-17 |
| Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)NCT00805324Demonstration of the efficacy of desloratadine in relieving the total nasal/non-nasal symptoms of seasonal allergic rhinitisOpen-label · Treatment | Phase 3 | Completed | Drug: Desloratadine | Rhinitis, Allergic, Seasonal, Asthma | 54 | Aug 2003actual | — | 2022-02-16 |
| A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin DNCT00806416results2010-02-12Part 1: The Total Urinary Excretion of Alendronate With Alendronate/Vitamin D Combination Tablet Relative to Alendronate TabletRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: alendronate sodium (+) cholecalciferol, Comparator: alendronate · Dietary supplement: Comparator: cholecalciferol (Vitamin D) | Osteoporosis | 244 | Aug 2003actual | — | 2022-02-08 |
| Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)NCT00794495The primary efficacy measure was the preference rates calculated from subject comparative evaluation.Randomized · Open-label · Other | Phase 4 | Completed | Drug: Desloratadine 5 mg (Clarinex), Cetirizine (Zyrtec) | Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis | 122 | Jul 2003actual | — | 2022-02-17 |
| Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)NCT00794768The primary efficacy measure was the preference rates calculated from subject comparative evaluation.Randomized · Open-label · Other | Phase 4 | Completed | Drug: desloratadine 5 mg, fexofenadine | Seasonal Allergic Rhinitis | 118 | Jul 2003actual | — | 2022-02-17 |
| Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475)NCT00817076Demonstration of the efficacy of desloratadine in relieving the total symptoms of atopic dermatitis through SCORAD IndexOpen-label · Treatment | Phase 3 | Completed | Drug: desloratadine | Dermatitis, Atopic | 40 | Jul 2003actual | — | 2022-02-16 |
| Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)NCT03885921Number of Participants Who Experience an Adverse Event (AE)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Ezetimibe, Atorvastatin, Simvastatin | Hypercholesterolemia | 44 | 2003-07-08actual | — | 2022-02-17 |
| A Randomized Trial Assessing Once Daily Administration of Mometasone Furoate DPI in Asthmatics (Study P02177)NCT00835094Between-treatment group comparisons (MF-DPI 400 mcg once daily in the morning compared to the evening) of daytime and nocturnal symptoms based on a 4 point scale.Randomized · Open-label · Treatment | Phase 4 | Completed | Device: Mometasone furoate, Mometasone furoate | Asthma | 216 | 2003-07-01actual | — | 2024-08-15 |
| A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)NCT00092651Plasma LDL-CRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653A, ezetimibe (+) simvastatin, Comparators: simvastatin and ezetimibe | Hypercholesterolemia | 1,398 | Jun 2003actual | — | 2024-08-23 |
| Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)NCT00805584Relief of allergy symptomsOpen-label · Treatment | Phase 4 | Completed | Drug: desloratadine | Rhinitis, Allergic, Seasonal | 311 | Jun 2003actual | — | 2022-02-17 |
| Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)NCT00783133The primary efficacy measure was the preference rates calculated from subject comparative evaluation.Randomized · Open-label · Other | Phase 4 | Completed | Drug: Desloratadine 5 mg, fexofenadine | Seasonal Allergic Rhinitis | 131 | 2003-06-01actual | — | 2024-08-15 |
| Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)NCT00651144Percent change from baseline in total cholesterol, LDL-C, HDL-C, and triglycerides.Randomized · Single-masked · Treatment | Phase 1 | Completed | Drug: Ezetimibe + Rosuvastatin, Rosuvastatin, Placebo, Ezetimibe | Hypercholesterolemia, Atherosclerosis | 40 | May 2003actual | — | 2022-02-17 |
| Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)NCT00794248The primary efficacy measure was the preference rates calculated from subject comparative evaluation.Randomized · Open-label · Other | Phase 4 | Completed | Drug: desloratadine 5 mg, fexofenadine | Seasonal Allergic Rhinitis | 122 | May 2003actual | — | 2022-02-17 |
| Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)NCT00794846The primary efficacy measure was the preference rates calculated from subject comparative evaluation.Randomized · Open-label · Other | Phase 4 | Completed | Drug: Desloratadine 5 mg (Clarinex), Cetirizine (Zyrtec) | Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis | 124 | May 2003actual | — | 2022-02-17 |
| A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524)NCT00817817The assessment of efficacy will be done by spirometry, determining the difference in FEV1 and PEFR measured by spirometry on baseline, 7, 14, 28, 42 and 56 days after initiation of MF dry powder inhaler (DPI) therapy.Randomized · Open-label · Treatment | Phase 3 | Completed | Device: MF, MF | Asthma | 93 | 2003-05-01actual | — | 2024-08-15 |
| Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)NCT00092716To evaluate the effect on the reduction in low density lipoprotein cholesterol (LDL-C) after the initial 6-week treatment period.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe / Duration of Treatment: 28 weeks, Comparator: atorvastatin / Duration of Treatment: 28 weeks | Hypercholesterolemia | 655 | Apr 2003actual | — | 2024-08-15 |
| Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836)NCT00867191The primary objective was to demonstrate the efficacy (as percentage of change from baseline) of desloratadine to improve the nasal total symptom score of SAR to cypress pollen.Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Placebo, Desloratadine | Seasonal Allergic Rhinitis | 233 | 2003-04-01actual | — | 2024-08-15 |
| A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)NCT00551447LDL-C measurement (target goal = <100 mg/dL)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe / Duration of Treatment: 27 Weeks, MK0733, simvastatin / Duration of Treatment: 27 Weeks, Comparator: simvastatin / Duration of Treatment: 27 Weeks | Coronary Disease | 616 | Mar 2003actual | — | 2024-08-15 |
| Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)NCT00092157Fasting triglyceride levels at 12 weeks.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0733, simvastatin, Comparator: simvastatin | Hypercholesterolemia | 571 | 2003-03-03actual | — | 2024-08-15 |
| A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165)NCT00140881Composite unscheduled acute health care resource utilisation (specific for asthma; unscheduled visits, GP attendance, ED attendance and hospital admission).Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: MK0476; montelukast sodium, Comparator: placebo | Asthma | 220 | 2003-02-14actual | — | 2024-08-14 |
| A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)NCT03882996Number of participants who experienced an adverse eventOpen-label · Treatment | Phase 3 | Completed | Drug: Ezetimibe, Atorvastatin | Hypercholesterolemia | 432 | 2003-02-04actual | — | 2022-02-17 |
| Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)NCT00551876Percent change in fasting LDL-C from baseline to the average of the Week 6/Week 12 measurementsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe / Duration of Treatment: 30 Weeks, Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks | Diabetes Mellitus, Type 2 | 214 | Jan 2003actual | — | 2024-08-15 |
| Health Assessment Study (0954-946)NCT00541684number of sexual intercourse events in a 2-week periodRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0954, /Duration of Treatment : 16 Weeks, Comparator : atenolol /Duration of Treatment : 16 Weeks | Hypertension | 143 | 2003-01-23actual | — | 2024-08-15 |
| A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)NCT00389740Bone Mineral Density (BMD) in PA lumbar spine at 12 monthsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0217, /Duration of Treatment : 12 Months, Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months | Osteoporosis, Postmenopausal | 400 | 2003-01-16actual | — | 2024-08-14 |
| Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)NCT00092105Co-Primary endpoints: (1) Area Under the Curve (AUC) for the percent fall from prechallenge FEV1 during allergen challenge; (2) Area Under the Curve for the increase from prechallenge Nasal Symptoms score during allergen challengeRandomized · Double-masked · Prevention | Phase 3 | Completed | Drug: MK0476, montelukast sodium, Comparator: placebo | Asthma, Bronchial, Rhinitis, Allergic, Perennial | 58 | 2003-01-01actual | — | 2024-08-14 |
| A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)NCT00700661asthma episodes in 2 - 5 year old childrenRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast, placebo (unspecified) | Asthma | 500 | Dec 2002actual | — | 2024-08-15 |
| Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)NCT00945035results2009-11-17Plasma Area Under the Curve (AUC(0 to Infinity)) for EtoricoxibRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: etoricoxib, Comparator: etoricoxib | Pain | 36 | Dec 2002actual | — | 2022-02-09 |
| A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)NCT01101464results2010-10-13Pharmacokinetic Parameter of Maximum Plasma Concentration (Cmax) of Two Differing Tablet Strengths (3 x 5 mg and 1 x 15 mg) of Sublingually Administered Org 5222 (Asenapine)Randomized · Open-label · Basic science | Phase 2 | Completed | Drug: Asenapine 3x5mg followed by 1x15mg, Asenapine 1x15mg followed by 3x5mg | Schizophrenia, Schizoaffective Disorder | 8 | Dec 2002actual | — | 2022-02-09 |
| Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)NCT00542087This study will assess the effectiveness of the study drug vs. a comparator to treat successfully OA-related joint pain (judged by WOMAC pain subscale).Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0663, etoricoxib / Duration of Treatment: 6 Weeks, Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks | Osteoarthritis | 516 | 2002-12-20actual | — | 2024-08-15 |
| An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)NCT00092729Overall analgesic effect as measured by the total pain relief score over 8 hours post dose (TOPAR8), sum of pain intensity difference over 8 hours post dose (SPID8), and patient's global evaluation at 8 and 24 hours post dose compared with placeboRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: etoricoxib (MK0663), Comparator: placebo (unspecified), Comparator: naproxen sodium | Dysmenorrhea | 129 | 2002-12-06actual | — | 2024-08-15 |
| Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)NCT00092209Mean trough SiDBP after 8 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0954A, hydrochlorothiazide (+) losartan potassium, Comparator: placebo, losartan, hydrochlorothiazide | Hypertension | 840 | Nov 2002actual | — | 2022-02-15 |
| A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)NCT00480662Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 monthsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: alendronate | Paget's Disease of Bone | 60 | Oct 2002actual | — | 2024-08-14 |
| HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)NCT00480805To determine the antihypertensive effectiveness of HYZAAR as compared to Ramipril as measure by SiSBP at Week 4Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks, Comparator : ramipril /Duration of Treatment : 8 Weeks | Type 2 Diabetes Mellitus, Hypertension | 312 | 2002-10-15actual | — | 2024-08-15 |
| Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)NCT00702585Participant Ovulation Rate in Monofollicular CyclesRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Org 36286, Placebo | Infertility | 55 | 2002-10-15actual | — | 2024-08-15 |
| Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)NCT00702806Median Puregon® Dose (IU) Required To Reach Criteria for Administration of Human Chorionic Gonadotropin (hCG) For Induction of Final Oocyte MaturationRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Org 36286, Puregon®, Orgalutran®, Pregnyl® | Infertility, In Vitro Fertilization | 99 | 2002-10-15actual | — | 2024-08-15 |
| A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)NCT00389896HDL-C raising effects after 6 weeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0733 / Duration of Treatment: 18 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks | HDL Cholesterol | 150 | 2002-10-04actual | — | 2024-08-15 |
| Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)NCT03882892Percentage of Participants Experiencing ≥1 Adverse Event (AE)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Ezetimibe, Atovastatin, Placebo | Hypercholesterolemia | 400 | 2002-08-08actual | — | 2024-05-10 |
| A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)NCT00489346Improvement of asthma with MK0476 and Fluticasone as measured by number of asthma rescue-free daysRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0476, montelukast sodium / Duration of Treatment: 1 Year, Comparator : fluticasone propionate / Duration of Treatment: 1 Year | Asthma, Bronchial | 994 | Jun 2002actual | — | 2024-08-15 |
| Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)NCT00974571results2010-06-07Mean Change From Baseline in Daytime Nasal Symptoms ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: cetirizine, Comparator: placebo | Perennial Allergic Rhinitis | 1,365 | May 2002actual | — | 2022-02-03 |
| Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)NCT0014098524h proteinuriaRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: MK0954, losartan potassium/Duration of Treatment: 20 weeks, Comparator: amlodipine / Duration of Treatment: 20 weeks | Renal Disorder | 97 | Jan 2002actual | — | 2022-02-16 |
| Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)NCT00963469results2010-06-09Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment PeriodRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: loratadine, Comparator: placebo | Seasonal Allergic Rhinitis | 1,079 | Nov 2001actual | — | 2022-02-03 |
| Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)NCT03867318Percentage of Participants Achieving Target Low-Density-Lipoprotein Cholesterol (LDL-C) Levels of ≤100 mg/dLRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Atorvastatin, Ezetimibe, Placebo for Ezetimibe, Placebo for Atorvastatin | Hypercholesterolemia | 621 | 2001-11-16actual | — | 2024-05-10 |
| Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)NCT00943397results2010-06-17Number of Clinical Adverse Experiences (CAEs) Reported by Patients With up to 52 Weeks of TreatmentRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: Usual Care | Asthma | 190 | Oct 2001actual | — | 2022-02-03 |
| Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)NCT00338260Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack)Randomized · Double-masked · Prevention | Phase 3 | Completed | Drug: MK0954, /Duration of Treatment : 5 Years, Comparator : atenolol /Duration of Treatment : 5 Years | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | 496 | Sep 2001actual | — | 2022-02-15 |
| Sitosterolemia Extension Study (0653-003)(COMPLETED)NCT00092807To assess the percent change relative to baseline in plasma sitosterol concentration after long-term treatment with MK0653 10 mg/day.Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe, Comparator: placebo | Lipid Metabolism, Inborn Errors, Heart Disease | 37 | 2001-09-18actual | — | 2024-08-15 |
| Sitosterolemia Extension Study (0653-004)(COMPLETED)NCT00092820Plasma sitosterol levels after 52 weeks.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0653, ezetimibe, Comparator: placebo | Lipid Metabolism, Inborn Errors, Heart Disease | 58 | 2001-09-18actual | — | 2024-08-15 |
| Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)NCT00972738results2010-06-16Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment PeriodRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: loratadine, Comparator: Placebo | Seasonal Allergic Rhinitis | 1,214 | Jul 2001actual | — | 2022-02-03 |
| An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)NCT03867110Percent Change from Baseline at Week 12 of Plasma Low Density Lipoprotein Cholesterol (LDL-C)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Ezetimibe 10 mg, Atorvastatin 10 mg, Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 80 mg | Hypercholesterolemia | 628 | 2001-07-27actual | — | 2024-05-10 |
| A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)NCT03882905Percentage Change from Baseline in LDL-C: Base StudyRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Ezetimibe, Placebo, Simivastatin, Statin | Primary Hypercholesterolemia | 769 | 2001-07-27actual | — | 2024-05-10 |
| A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED)NCT00968149results2009-12-11Number of Patients With Clinical Adverse Experiences (CAEs)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: Placebo | Seasonal Allergic Rhinitis | 413 | Jun 2001actual | — | 2022-02-03 |
| Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)NCT03884452Percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C) measured directlyRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Atorvastatin, Simvastatin, Ezetimibe, Placebo for Ezetimibe | Familial Hypercholesterolemia | 50 | 2001-05-24actual | — | 2024-05-10 |
| Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )NCT00968201results2010-08-03Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base StudyRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: Placebo | Asthma | 689 | Mar 2001actual | — | 2022-02-03 |
| A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)NCT00308347Combined endpoint of doubling of serum creatinine, ESRD or death.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0954, losartan / Duration of Treatment: mean 3.4 years, Placebo / Duration of Treatment: mean 3.4 years | Type 2 Diabetes, Nephropathy | 1,513 | Feb 2001actual | — | 2022-02-15 |
| Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study (0476-176)NCT00943683results2010-06-17Number of Clinical Adverse Experiences (CAEs) Reported by Patients During the 6-weeks of TreatmentRandomized · Double-masked · Treatment | Not applicable | Completed | Drug: montelukast sodium, Comparator: Placebo | Asthma | 256 | Feb 2001actual | — | 2022-02-03 |
| An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)NCT00647933Maximum number of follicles >= 5 mm (nmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Org 36286, Lyndiol® | Infertility | 24 | Dec 2000actual | — | 2022-02-03 |
| Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042)NCT00393211Low back pain intensity scale (0-100 mm VAS) over 4 weeks compared to placeboRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0663, Etoricoxib / Duration of Treatment : 12 Weeks, Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks | Recurrent Low Back Pain | 319 | Nov 2000actual | — | 2022-02-18 |
| Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)NCT00393354Low back pain intensity scale (0-100 mm VAS) over 4 weeks compared to placeboRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0663, Etoricoxib / Duration of Treatment : 12 Weeks, Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks | Recurrent Low Back Pain | 325 | Nov 2000actual | — | 2022-02-18 |
| A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075)NCT00140946Percentage of days of asthma exacerbationsRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: MK0476; montelukast sodium/Duration of Treatment: 16 weeks, Comparator: placebo / Duration of Treatment: 16 weeks | Asthma | 546 | Oct 2000actual | — | 2022-02-02 |
| A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)NCT00960141results2010-06-09Mean Change From Baseline in Daytime Nasal Symptoms ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, Comparator: loratadine, Comparator: placebo | Seasonal Allergic Rhinitis | 829 | Oct 2000actual | — | 2022-02-03 |
| Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)NCT00979901results2010-06-08Mean Change From Baseline in Daytime Nasal Symptoms Score Over 2 WeeksRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Comparator: montelukast, Comparator: loratadine, Comparator: placebo, Comparator: montelukast/loratadine | Seasonal Allergic Rhinitis | 1,577 | May 2000actual | — | 2022-02-09 |
| Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)NCT00396175Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0906, finasteride / Duration of Treatment : 48 Weeks, Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks | Androgenetic Alopecia | 355 | Jan 2000actual | — | 2022-02-17 |
| Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)NCT00963599results2010-06-16Mean Change From Baseline in Daytime Nasal Symptoms ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Comparator: montelukast/loratadine, Comparator: montelukast, Comparator: loratadine, Comparator: placebo | Seasonal Allergic Rhinitis | 907 | Nov 1999actual | — | 2022-02-09 |
| Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)NCT00242489WOMAC Pain Subscale, Investigator Global Assessment of Disease Status, and Patient Global Assessment of Response to Therapy (not a primary endpoint in extension periods)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks), Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks | Osteoarthritis | 1,167 | Feb 1999actual | — | 2022-02-18 |
| A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)NCT00398606BMD of the lumbar spine determined by a DEXA scan at 2 yearsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: MK0217, alendronate sodium / Duration of Treatment : 2 Years, Comparator : calcium carbonate /Duration of Treatment : 2 Years | Osteoporosis, Postmenopausal | 650 | Feb 1998actual | — | 2022-02-03 |
| Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)NCT01286207results2011-06-10Percent of Patient's Headaches With Pain Relief at 2 Hours After the Initial Dose of Test DrugRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: Rizatriptan 5 mg, Rizatriptan 10 mg, Standard Care | Migraine Disorders | 1,959 | May 1997actual | — | 2022-02-03 |
| Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)NCT03879772results2019-08-12Change From Baseline in the Total Nasal Symptom Score (TNSS) at Day 8 as Assessed by InvestigatorRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Mometasone furoate nasal spray, Beclomethasone dipropionate nasal spray, Placebo nasal spray, Chlorpheniramine maleate syrup | Rhinitis, Allergic, Seasonal | 679 | 1996-07-01actual | — | 2022-02-09 |
| MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)NCT00897104results2010-07-23Pain Relief at 2 Hours After TreatmentRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: rizatriptan benzoate (MK0462), Comparator: sumatriptan, Comparator: Placebo | Migraine Headache | 933 | May 1996actual | — | 2022-02-03 |
| Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)NCT00898677results2009-07-14Pain Relief at 2 Hours After DoseRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: rizatriptan benzoate, rizatriptan benzoate, Comparator: sumatriptan, Comparator: Placebo | Migraine Headache | 1,268 | May 1996actual | — | 2022-02-03 |
| The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)NCT00911547results2010-06-09Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) in Patients With Chronic AsthmaRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: montelukast sodium, beclomethasone, Placebo inhaler, placebo tablet | Asthma | 642 | Apr 1996actual | — | 2022-02-03 |
| MK0462 in Treatment of Migraine With Recurrence (MK0462-022)NCT00897949results2011-05-04Pain Relief at 2 Hours After the Initial Dose of Test DrugRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: rizatriptan benzoate (MK0462), Comparator: placebo | Migraine Headache | 1,473 | Jan 1996actual | — | 2022-02-03 |
| Treatment of Multiple Attacks of Acute Migraine (0462-025)NCT00899379results2010-07-15Pain Relief at 2 Hours During the First Migraine Attack PeriodRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: rizatriptan benzoate, Comparator: Placebo | Migraine Headache | 473 | Jan 1996actual | — | 2022-02-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19